Hybrid enzymes

ABSTRACT

The present invention relates to a polypeptide and the use thereof.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims, under 35 U.S.C. 119, priority of Danishapplication nos. PA 2004 01976, filed Dec. 22, 2004, PA 2005 01261,filed Sep. 9, 2005, and the benefit of U.S. provisional application Nos.60/639,181, filed Dec. 22, 2004 and 60/717,274, filed Sep. 14, 2005, thecontents of which are fully incorporated herein by reference.

SEQUENCE LISTING

This application contains a sequence listing. A computer readable formcontaining the sequence listing accompanies this application, and thecomputer readable form of the sequence listing is hereby incorporated byreference.

FIELD OF THE INVENTION

The present invention relates, inter alia, to hybrid enzymes comprisinga carbohydrate binding module and having endo-amylase activity. Theenzymes may be applied in processes comprising starch modificationand/or degradation, or in dough making processes.

BACKGROUND OF THE INVENTION

Bacterial endo-amylases are used in a large number of processes, e.g.,for liquefaction of starch in processes where starch is modified, and/ordegraded to smaller polymers or monomers of glucose. The degradationproducts may used in the industry, e.g., as maltose and/or fructosesyrups or further processed in a fermentation step to a fermentationproduct, e.g., ethanol. The bacterial endo-amylases are used in bakingto give additional softness and a better moistness of the bread crumb.However, the endo-amylases are easy to overdose which may results ingumminess and an undesirable loss in elasticity in the baked product.There is a need for endo-amylases with improved properties for use invarious processes, e.g., within starch processing and baking.

SUMMARY OF THE INVENTION

The present inventors have now surprisingly discovered that by additionof a carbohydrate binding module (CBM) to an endo-amylase the catalyticactivity of the endo-amylase can be modified thereby resulting in anincreased baking performance compared to the wild type enzyme. There isno significant change in the taste or smell of the baked product.Without being bound by theory it is suggested that the effect is due toan increased activity towards raw starch in the dough conferred by theCBM, and/or a reduced activity towards the heated starch in the bakingbread conferred by the CBM. The endo-amylase with a CBM can be used as abaking enzyme with less risk of overdosing compared to the enzymewithout a CBM. Such hybrids consisting of a polypeptide havingendo-amylase activity and a carbohydrate binding module, primarilyhaving affinity for starch like e.g. the CBM20, have the advantage overexisting endo-amylases that by selecting a catalytic domain with desireproperties e.g. the pH profile, the temperature profile, the oxidationresistance, the calcium stability, the substrate affinity or the productprofile can be combined with a carbohydrate binding module with strongeror weaker binding affinities, e.g., specific affinities for amylose,specific affinities for amylopectin or affinities for specific structurein the carbohydrate. The hybrid may be used as a baking additive, e.g.,as an anti-staling enzyme.

The present inventors have further surprisingly discovered that byadding a carbohydrate-binding module (CBM) to an endo-amylase theactivity and specificity can be altered thereby increasing the efficacyof various starch degrading processes, e.g., comprising degradation ofraw, e.g., ungelatinized starch as well as gelatinized starch. Due tothe superior hydrolysis activity of these endo-amylases having a CBM theoverall starch conversion process can be performed without having togelatinize the starch, i.e. the endo-amylases having a CBM hydrolysesgranular starch in a raw starch process as well as fully or partiallygelatinized starch in a traditional starch process.

Accordingly the invention provides in a first aspect a polypeptide whichpolypeptide is a hybrid comprising; a first amino acid sequence havingendo-amylase activity and a second amino acid sequence comprising acarbohydrate-binding module. Preferably said first amino acid sequenceand/or said amino acid second sequence is derived from a bacterium. Thesecond amino acid sequence has preferably at least 60% identity to theamino acid sequence shown as amino acid residues 485 to 586 in SEQ IDNO:2 and/or the first amino acid sequence has at least 60% identity tothe amino acid sequence shown in SEQ ID NO:35.

In a second aspect the invention provides a process for preparing adough or an edible product made from a dough, which process comprisesadding the polypeptide of the first aspect to a dough.

In a third and a fourth aspect the invention provides a compositioncomprising the polypeptide of the first aspect, and a dough- orbread-improving additive in the form of a granulate or agglomeratedpowder comprising the polypeptide of the first aspect.

In a fifth aspect the invention provides a process for designing apolypeptide suitable for baking, said process comprising; providing afirst amino acid sequence having endo-amylase activity, and a secondamino acid sequence comprising a carbohydrate-binding module; whereinsaid first amino acid sequence is derived from a bacterium; providing asecond amino acid sequence comprising a carbohydrate-binding module; andconstructing a polypeptide comprising said first amino acid sequencewith said second amino acid sequence.

In a sixth aspect the invention provides a process for preparingcomposition, e.g., a bread improving additive, is produced in a processcomprising the steps of; a) providing a first amino acid sequence havingendo-amylase activity; b) providing a second amino acid sequencecomprising a carbohydrate-binding module; c) and constructing apolypeptide comprising said first amino acid sequence and second aminoacid sequence; d) providing a DNA sequence encoding said polypeptide; e)expressing said DNA sequence in a suitable host cell and recovering saidpolypeptide; f) adding said polypeptide to flour or to a granulate oragglomerated powder.

In a seventh aspect the invention provides a process for preparing adough or an edible product made from a dough, which process comprises;providing a first amino acid sequence having endo-amylase activity;providing a second amino acid sequence comprising a carbohydrate-bindingmodule; and constructing a polypeptide comprising said first amino acidsequence and second amino acid sequence; providing a DNA sequenceencoding said polypeptide; expressing said DNA sequence in a suitablehost cell and recovering said polypeptide; and adding said polypeptideto a dough.

In a eigth aspect the invention provides a process for saccharifyingstarch, wherein a starch is treated with the polypeptide according tothe first aspect.

In a ninth aspect the invention provides a process comprising;contacting a starch with a polypeptide comprising a first amino acidsequence having endo-amylase activity, and a second amino acid sequencecomprising a carbohydrate-binding module; wherein said first amino acidsequence and/or said second amino acid sequence is derived from abacterium; incubating said starch with said polypeptide for a time andat a temperature sufficient to achieve conversion of at least 90% w/w ofsaid starch substrate into fermentable sugars; fermenting to produce afermentation product, and optionally recovering the fermentationproduct, wherein said polypeptide may be a polypeptide according to thefirst aspect

In an tenth aspect the invention provides a process comprising; a)contacting a starch substrate with a yeast cell transformed to express apolypeptide comprising a first amino acid sequence having endo-amylaseactivity, and a second amino acid sequence comprising acarbohydrate-binding module; b) holding said starch substrate with saidyeast for a time and at a temperature sufficient to achieve conversionof at least 90% w/w of said starch substrate into fermentable sugars; c)fermenting to produce ethanol; optionally recovering ethanol; whereinsteps a, b, and c are performed separately or simultaneously and whereinsaid polypeptide may be a polypeptide according to the first aspect

In an eleventh aspect the invention provides a process of producingethanol from starch-containing material by fermentation, said processcomprises: a) liquefying said starch-containing material with apolypeptide comprising a first amino acid sequence having endo-amylaseactivity, and a second amino acid sequence comprising acarbohydrate-binding module; wherein said first amino acid sequenceand/or second amino acid sequence is derived from a bacterium; b)saccharifying the liquefied mash obtained; c) fermenting the materialobtained in step (b) in the presence of a fermenting organism.

In still further aspects the invention provides a DNA sequence encodinga polypeptide according to the first aspect, a DNA construct comprisingsaid DNA sequence, a recombinant expression vector which carries saidDNA construct, a host cell which is transformed with said DNA constructor said vector, said host cell being a bacterium or a fungal cell, aplant cell, or a yeast cell.

DETAILED DESCRIPTION OF THE INVENTION

Hybrid Enzymes

The polypeptide of the invention may be a hybrid enzyme comprises afirst amino acid sequence having endo-amylase activity, and a secondamino acid sequence comprising a carbohydrate-binding module (CBM). Thehybrid may be produced by fusion of a first DNA sequences encoding afirst amino acid sequences and a second DNA sequences encoding a secondamino acid sequences, or the hybrid may be produced as a completelysynthetic gene based on knowledge of the amino acid sequences ofsuitable CBMs, linkers and catalytic domains.

The terms “hybrid enzyme” (also referred to as “fusion protein”,“hybrid”, hybrid polypeptide” or “hybrid protein) is used herein tocharacterize the polypeptides of the invention comprising a first aminoacid sequence comprising at least one catalytic module havingendo-amylase activity and a second amino acid sequence comprising atleast one carbohydrate-binding module wherein the first and the secondare derived from different sources. The term “source” being understoodas e.g., but not limited, to a parent enzyme, or a variant thereof,e.g., an amylase or glucoamylase, or other catalytic activity comprisinga suitable catalytic module and/or a suitable CBM and/or a suitablelinker. However the CBM may also be derived from a polypeptide having nocatalytic activity. The first and the second amino acid sequence may bederived from the same bacterial strain, from strains within the samespecies, from closely related species or less related organisms.Preferably the first and the second amino acid sequence of the hybridsderived from different sources, e.g., from different enzymes from thesame strain and/or species, or e.g., from strains within differentspecies.

Enzyme classification numbers (EC numbers) referred to in the presentspecification are in accordance with the Recommendations of theNomenclature Committee of the International Union of Biochemistry andMolecular Biology (http://www.chem.qmw.ac.uk/iubmb/enzyme/).

Hybrid enzymes as referred to herein include species comprising an aminoacid sequence of an endo-amylase, i.e. an alpha-amylase (EC 3.2.1.1)which is linked (i.e. covalently bound) to an amino acid sequencecomprising a carbohydrate-binding module (CBM). The hybrid enzyme isthus an enzyme capable of catalyzing hydrolysis of starch in anendo-fashion.

CBM-containing hybrid enzymes, as well as detailed descriptions of thepreparation and purification thereof, are known in the art [see, e.g.,WO 90/00609, WO 94/24158 and WO 95/16782, as well as Greenwood et al.Biotechnology and Bioengineering 44 (1994) pp. 1295-1305]. They may,e.g., be prepared by transforming into a host cell a DNA constructcomprising at least a fragment of DNA encoding the carbohydrate-bindingmodule ligated, with or without a linker, to a DNA sequence encoding theenzyme of interest, and growing the transformed host cell to express thefused gene. The linker may be a bond (i.e. comprising 0 residues), or ashort linking group comprising from about 2 to about 100 carbon atoms,in particular of from 2 to 40 carbon atoms. However, the linker ispreferably a sequence of 0 amino acid residues (e.g., just a bond) or itis from about 2 to about 100 amino acid residues, more preferably offrom 2 to 40 amino acid residues, such as from 2 to 15 amino acidresidues. Preferably the linker is not sensitive to or at least has lowsensitivity towards hydrolysis by a protease, which e.g., may be presentduring production of the hybrid and/or during the industrial applicationof the hybrid. The CBM in a hybrid enzyme of the type in question may bepositioned C-terminally, N-terminally or internally in the hybridenzyme. In an embodiment a polypeptide may comprise more than one CBM,e.g., two CBMs; one positioned C-terminally, the other N-terminally orthe two CBMs in tandem positioned C-terminally, N-terminally orinternally. However, polypeptides with more than two CBMs are equallycontemplated.

Polypeptide Identity

The term polypeptide “identity” is understood as the degree of identitybetween two sequences indicating a derivation of the first sequence fromthe second. The identity may suitably be determined by means of computerprograms known in the art such as GAP provided in the GCG programpackage (Program Manual for the Wisconsin Package, Version 8, August1994, Genetics Computer Group, 575 Science Drive, Madison, Wis., USA53711) (Needleman, S. B. and Wunsch, C. D., (1970), Journal of MolecularBiology, 48, 443-453. The following settings for amino acid sequencecomparison are used: GAP creation penalty of 3.0 and GAP extensionpenalty of 0.1. The relevant part of the amino acid sequence for theidentity determination is the mature polypeptide, i.e. without thesignal peptide.

Carbohydrate-Binding Modules

A carbohydrate-binding module (CBM), or as often referred to, acarbohydrate-binding domain (CBD), is a polypeptide amino acid sequencewhich binds preferentially to a poly- or oligosaccharide (carbohydrate),frequently—but not necessarily exclusively—to a water-insoluble(including crystalline) form thereof.

CBMs derived from starch degrading enzymes are often referred to asstarch-binding modules or SBMs (CBMs which may occur in certainamylolytic enzymes, such as certain glucoamylases, or in enzymes such ascyclodextrin glucanotransferases, or in endo-amylases). SBMs are oftenreferred to as SBDs (Starch Binding Domains). Prefered for the inventionare CBMs which are Starch Binding Modules.

CBMs are found as integral parts of large polypeptides or proteinsconsisting of two or more polypeptide amino acid sequence regions,especially in hydrolytic enzymes (hydrolases) which typically comprise acatalytic module containing the active site for substrate hydrolysis anda carbohydrate-binding module (CBM) for binding to the carbohydratesubstrate in question. Such enzymes can comprise more than one catalyticmodule and one, two or three CBMs, and optionally further comprise oneor more polypeptide amino acid sequence regions linking the CBM(s) withthe catalytic module(s), a region of the latter type usually beingdenoted a “linker”. CBMs have also been found in algae, e.g., in the redalga Porphyra purpurea in the form of a non-hydrolyticpolysaccharide-binding protein.

In proteins/polypeptides in which CBMs occur (e.g., enzymes, typicallyhydrolytic enzymes), a CBM may be located at the N or C terminus or atan internal position.

That part of a polypeptide or protein (e.g., hydrolytic enzyme) whichconstitutes a CBM per se typically consists of more than about 30 andless than about 250 amino acid residues. The “Carbohydrate-BindingModule of Family 20” or a CBM-20 module is in the context of thisinvention defined as a sequence of approximately 100 amino acids havingat least 45% identity to the Carbohydrate-Binding Module (CBM) of thepolypeptide disclosed in FIG. 1 by Joergensen et al (1997) inBiotechnol. Lett. 19:1027-1031. The CBM comprises the last 102 aminoacids of the polypeptide, i.e. the subsequence from amino acid 582 toamino acid 683. The numbering of Glycoside Hydrolase Families applied inthis disclosure follows the concept of Coutinho, P. M. & Henrissat, B.(1999) CAZy—Carbohydrate-Active Enzymes server at URL:http://afmb.cnrs-mrs.fr/˜cazy/CAZY/index.html or alternatively Coutinho,P. M. & Henrissat, B. 1999; The modular structure of cellulases andother carbohydrate-active enzymes: an integrated database approach. In“Genetics, Biochemistry and Ecology of Cellulose Degradation”, K.Ohmiya, K. Hayashi, K. Sakka, Y. Kobayashi, S. Karita and T. Kimuraeds., Uni Publishers Co., Tokyo, pp. 15-23, and Bourne, Y.& Henrissat,B. 2001; Glycoside hydrolases and glycosyltransferases: families andfunctional modules, Current Opinion in Structural Biology 11:593-600.

Examples of enzymes which comprise a CBM suitable for use in the contextof the invention are endo-amylases (i.e. alpha-amylases in EC 3.2.1.1),maltogenic alpha-amylases (EC 3.2.1.133), glucoamylases (EC 3.2.1.3) orfrom CGTases (EC 2.4.1.19).

Preferred for the invention is CBMs of Carbohydrate-Binding ModuleFamily 20. CBMs of Carbohydrate-Binding Module Family 20 suitable forthe invention may be derived from beta-amylases of Bacillus cereus(SWISSPROT P36924), or from CGTases of Bacillus circulans (SWISSPROTP43379). Also preferred for the invention is any CBM having at least60%, at least 70%, at least 80% or even at least 90% identity to any ofthe afore mentioned CBM amino acid sequences. Further suitable CBMs ofCarbohydrate-Binding Module Family 20 may be found at URL:http://afmb.cnrs-mrs.fr/˜cazy/CAZY/index.html).

Once a nucleotide sequence encoding the substrate-binding(carbohydrate-binding) region has been identified, either as cDNA orchromosomal DNA, it may then be manipulated in a variety of ways to fuseit to a DNA sequence encoding the enzyme of interest. The DNA fragmentencoding the carbohydrate-binding amino acid sequence and the DNAencoding the enzyme of interest are then ligated with or without alinker. The resulting ligated DNA may then be manipulated in a varietyof ways to achieve expression.

CBMs deriving from bacteria will generally be suitable for use in thecontext of the invention, however, preferred are CBMs of bacillusorigin, such as a CBM20 from Bacillus flavothermus (Syn. Anoxybacilluscontaminans), preferably from amylase AMY1048 (SEQ ID NO:2 herein),AMY1039, or AMY1079 (disclosed as respectively SEQ ID NO1, 2 and 3 inPCT/US2004/023031 [NZ10474]), the Bacillus amylases disclosed in WO2002068589 from Diversa, Bacillus sp. TS23 (Korea) (Lin, L.-L.;Submitted (1-Mar.-1995) to the EMBL/GenBank/DDBJ databases. Long-LiuLin, Food Industry Research Institute, Culture Collection and ResearchCenter, 331 Food Road, Hsinchu, Taiwan 300, Republic of China).

In a particular embodiment the CBM sequence has the amino acid sequenceshown as amino acid residues 485 to 586 in SEQ ID NO:2 or the CBMsequence has an amino acid sequence having at least 60%, at least 70%,at least 80% or even at least 90% identity to the afore mentioned aminoacid sequence.

In another preferred embodiment the CBM sequence has an amino acidsequence which differs from the amino acid sequence shown as amino acidresidues 485 to 586 in SEQ ID NO:2 in no more than 10 positions, no morethan 9 positions, no more than 8 positions, no more than 7 positions, nomore than 6 positions, no more than 5 positions, no more than 4positions, no more than 3 positions, no more than 2 positions, or evenno more than 1 position.

Endo-Amylase Sequence

Endo-amylases which are appropriate as the basis for CBM/amylase hybridsof the types employed in the context of the present invention includethose of bacterial origin and having endo-amylase activity. Theendo-activity of the amylase may be determined according to the assay inthe “Materials and methods” section of the present application.Preferred are endo-amylase derived from Bacillus sp., particularly fromB. licheniformis, B. amyloliquefaciens, B. stearothermophilus or B.flavothermus. The endo-amylase is preferably an endo-amylase having atleast 60%, at least 70%, at least 80% or even at least 90% identity tothe amylase from Bacillus licheniformis (BLA, SEQ ID NO:8 inWO2002/010355) shown in SEQ ID NO:35 herein. This includes but are notlimited to the the amylase from B. licheniformis variant LE429(WO2002/010355) shown in SEQ ID NO:41 herein, the amylase from B.stearothermophilus (BSG, SEQ ID NO:6 in WO2002/010355) shown in SEQ IDNO:36 herein, the amylase from B. amyloliquefacience (BAN, SEQ ID NO:10in WO2002/010355) shown in SEQ ID NO:37 herein, the amylase from B.halodurance SP722 (SEQ ID NO:4 in WO2002/010355) shown in SEQ ID NO:38herein, SP690 (WO9526397) shown in SEQ ID NO:39 herein, the amylase fromM560 (SEQ ID NO:12 in WO2002/010355) shown in SEQ ID:40 herein, theamylase from alkaline Bacillus strains like e.g., SP707 (Tsukamoto etal., Biochemical and Biophysical Research Communications, 151 (1988),pp. 25-31.), the amylase KSM-AP1378 (WO9700324/KAO), the amylasesKSM-K36 and KSM-K38 (EP 1,022,334-A/KAO), the amylase SP7-7(WO0210356/Henkel), and the amylase AAI-6 (WO0060058), AMRK385(PCT/DK01/00133)—fragments, variants or truncated forms of above. Theendo-amylase sequence may also be derived from Pseudomonassaccharophilia, such as from the amylase disclosed as SEQ ID NO:1 in WO2004111217. Preferably endo-amylase sequence comprises the amino acidresidues 1 to 417 shown in SEQ ID NO:42 herein.

Preferably the endo-amylase is a wild type enzyme or the endo-amylase isa variant endo-amylases comprising amino acid modifications leading toincreased activity and/or increased protein stability at low pH, and/orat high pH, increased stability towards calcium depletion, and/orincreased stability at elevated temperature. Chemically or geneticallymodified mutants of such endo-amylases are included in this connection.

The B. licheniformis endo-amylase BLA shown in SEQ ID NO:35 is a wildtype amylase made up of a catalytic fragment of 483 amino acid. Thecatalytic domain can be divided into the central core-domain harboringthe catalytic center and a C domain c-terminal to the catalytic domain.In Seq. ID 8/NN10062 the catalytic core domain consist of the first 396amino acids and the C domain is defined as the amino acids from 397 to483

The variant of the B. licheniformis endo-amylase, LE429 shown in SEQ IDNO:41 consist of a catalytic fragment of 481 amino acid. The catalyticdomain can be divided into the central core-domain harboring thecatalytic center and a C domain c-terminal to the catalytic domain. InSEQ ID NO:41 the catalytic core domain consist of the first 394 aminoacids and the C domain is defined as the amino acids from 395 to 481.

The B. amyloliquefacience endo-amylase, BAN shown in SEQ ID NO:37 is awild type amylase made up of a catalytic fragment of 483 amino acid. Thecatalytic domain can be divided into the central core-domain harboringthe catalytic center and a C domain c-terminal to the catalytic domain.In SEQ ID NO:37 the catalytic core domain consist of the first 396 aminoacids and the C domain is defined as the amino acids from 397 to 483.

The B. stearothermophilus endo-amylase, BSG shown in SEQ ID NO:36 is awild type amylase made up of a catalytic fragment of 483 amino acid andin addition a c-terminal extension. The catalytic domain can further bedivided into the central core-domain harboring the catalytic center anda C domain c-terminal to the catalytic domain. In SEQ ID NO:36 thecatalytic core domain consist of the first 396 aa, the C domain isdefined as the amino acids from 397 to 483 and the c-terminal extensionis defines as amino acids 484 to 515.

The B. halodurance endo-amylase SP722 shown in SEQ ID NO:38 is a wildtype amylase made up of a catalytic fragment of 485 amino acid. The coredomain can further be divided into the central AB-domain harboring thecatalytic center and a C domain c-terminal to the catalytic domain. InSEQ ID NO:38 the catalytic core domain consist of the first 398 aminoacids and the C domain is defined as the amino acids from 399 to 485.

The alkaline Bacillus endo-amylase, AA560 shown in SEQ ID:40 herein is awild type amylase made up of a catalytic fragment of 485 amino acid. Thecore domain can further be divided into the central AB-domain harboringthe catalytic center and a C domain c-terminal to the catalytic domain.The catalytic core domain consist of the first 398 amino acids and the Cdomain is defined as the amino acids from 399 to 485. The catalytic coredomain is encoded by nucleotide 1-1194 and the C domain is encoded bythe nucleotides 1189-1455.

In a particular embodiment of the first aspect the endo-amylase sequencehas the amino acid sequence shown in SEQ ID NO:35, SEQ ID NO:36, SEQ IDNO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ IDNO:42 or the endo-amylase sequence has an amino acid sequence having atleast 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97% or even at least 99%identity to any of the afore mentioned amino acid sequences.

In yet another preferred embodiment of the first aspect the endo-amylasesequence has an amino acid sequence which differs from any of the aminoacid sequence amino acid sequences shown in SEQ ID NO:35, SEQ ID NO:36,SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41,SEQ ID NO:42 in no more than 10 positions, no more than 9 positions, nomore than 8 positions, no more than 7 positions, no more than 6positions, no more than 5 positions, no more than 4 positions, no morethan 3 positions, no more than 2 positions, or even no more than 1position.

In a preferred embodiment of the first aspect the endo-amylase sequencehas an amino acid sequence as shown in SEQ ID:40 (M560), and comprisingone or more of the following alterations R118K, D183*, G184*, N195F,R320K and R458K.

In another particularly preferred embodiment of the first aspect theendo-amylase sequence has an amino acid sequence as shown in SEQ ID:40,and comprising one or more, e.g., such as all, of the followingalterations R118K, D183*, G184*, N195F, R320K, R458K, N33S, D36N, K37L,E391I, Q394R, K395D, T452Y and N484P.

In another particularly preferred embodiment of the first aspect theendo-amylase sequence has an amino acid sequence as shown in SEQ ID:40,and comprising one or more, e.g., such as all, of the followingalterations R118K, D183*, G184*, N195F, R320K, R458K and N484P.

In yet another highly preferred embodiment of the first aspect theendo-amylase sequence has an amino acid sequence as shown in SEQ IDNO:37 and comprise one or more, e.g such as all of the followingalterations: S31A, D32N, 133L, E178*, G179*, N190F, K3891, K392R, E393D,V508A

Preferred Hybrids

In a particular embodiment the hybrid of the invention has amino acidsequence shown in SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10,SEQ ID NO:12, SEQ ID NO:14 or the hybrid of the invention has an aminoacid sequence having at least 60%, at least 70%, at least 80% or even atleast 90% identity to any of the afore mentioned amino acid sequences.

In yet another preferred embodiment the hybrid of the invention has anamino acid sequence which differs from the amino acid sequence aminoacid sequence shown in SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ IDNO:10, SEQ ID NO:12, SEQ ID NO:14 in no more than 10 positions, no morethan 9 positions, no more than 8 positions, no more than 7 positions, nomore than 6 positions, no more than 5 positions, no more than 4positions, no more than 3 positions, no more than 2 positions, or evenno more than 1 position.

In a preferred embodiment the polypeptide of the invention comprises a)the catalytic domain shown in SEQ ID NO:40 or a homologous catalyticdomain, and b) the CBM shown as residue 485 to 585 of SEQ ID NO:2,wherein one or more, or preferably all, of the following substitutionshave been introduced: R118K, D183*, G184*, N195F, R320K, R458K, N33S,D36N, K37L, E391I, Q394R, K395D, T452Y and N484P, using the numbering ofSEQ ID NO: 40.

In another preferred embodiment the polypeptide of the inventioncomprises the catalytic domain shown in SEQ ID NO:40 or a homologouscatalytic domain, and b) the CBM shown as residue 485 to 585 of SEQ IDNO:2, wherein one or more, or preferably all, of the followingsubstitutions have been introduced: R118K, D183*, G184*, N195F, R320K,R458K and N484P, using the numbering of SEQ ID NO: 40.

In yet another preferred embodiment the polypeptide of the inventioncomprises the catalytic domain shown in SEQ ID: 37 and comprise one ormore, e.g. such as all of the following alterations: S31A, D32N, 133L,E178*, G179*, N190F, K3891, K392R, E393D, V508A and a CBM having theamino acid sequence shown as amino acid residues 485 to 586 in SEQ IDNO:2.

Stabilization of Hybrids

A hybrid of the invention may be volatile to proteolytic attack if theCBM and catalytic domain proteins do not form sufficiently tightprotein-protein interactions. However, the stability of the hybrid canbe improved by introducing substitutions on the surface of either of theproteins to create a stable hybrid.

The present inventors have identified the following amino acid residueson the surface of bacterial endo-amylases, e.g., such polypeptideshaving at least 60% identity to the amylase from Bacillus licheniformis(SEQ ID NO:8), to be in close contact with the CBM when comprised in thehybrid of the invention, i.e. within less than 5.0 Å distance. Theseresidues are suitable targets for mutations in order to make a stablehybrid: 12, 29, 30, 32, 33, 34, 35, 36, 37, 38, 368, 371, 372, 381, 383,384, 386, 387, 388, 389, 390, 391, 392, 394, 395, 396, 422, 423, 448,449, 450, 451, 452, 453, 454, 455, 456, 458, 459, 460, 461, 483, 484,485 using the numbering of SEQ ID NO: 40. Preferably the catalyticdomain of the hybrid of the invention comprises one or moresubstitutions in positions corresponding to these residues.

In a preferred embodiment the hybrid of the invention comprises a) thecatalytic domain shown in SE ID NO:40 or a homologous catalytic domain,and b) the CBM shown as residue 485 to 585 of SEQ ID NO:2, wherein oneor more, or preferably all, of the following substitutions have beenintroduced: N33S, K35S/A, D36A/N/S, K37L, E391I, Q394R, K395D, N484A/Pusing the numbering of SEQ ID NO: 40.

On the surface of the CBM protruding towards the catalytic domain of thehybrid the following residues are found in close contact with thecatalytic domain, i.e. within 5.0 Å distance, and these residues aresuitable targets for mutations in order to make a stable hybrid: 485,486, 487, 488, 507, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521,522, 523, 524, 526, 538, 539, 540, 541, 553, 554, 555, 556, 557, 558,559 using the numbering of SEQ ID NO: 2.

Expression Vectors

The present invention also relates to recombinant expression vectorswhich may comprise a DNA sequence encoding the hybrid enzyme, apromoter, a signal peptide sequence, and transcriptional andtranslational stop signals. The various DNA and control sequencesdescribed above may be joined together to produce a recombinantexpression vector which may include one or more convenient restrictionsites to allow for insertion or substitution of the DNA sequenceencoding the polypeptide at such sites. Alternatively, the DNA sequenceof the present invention may be expressed by inserting the DNA sequenceor a DNA construct comprising the sequence into an appropriate vectorfor expression. In creating the expression vector, the coding sequenceis located in the vector so that the coding sequence is operably linkedwith the appropriate control sequences for expression, and possiblysecretion.

The recombinant expression vector may be any vector (e.g., a plasmid orvirus), which can be conveniently subjected to recombinant DNAprocedures and can bring about the expression of the DNA sequence. Thechoice of the vector will typically depend on the compatibility of thevector with the host cell into which the vector is to be introduced. Thevectors may be linear or closed circular plasmids. The vector may be anautonomously replicating vector, i.e. a vector which exists as anextrachromosomal entity, the replication of which is independent ofchromosomal replication, e.g., a plasmid, an extrachromosomal element, aminichromosome, a cosmid or an artificial chromosome. The vector maycontain any means for assuring self-replication. Alternatively, thevector may be one which, when introduced into the host cell, isintegrated into the genome and replicated together with thechromosome(s) into which it has been integrated. The vector system maybe a single vector or plasmid or two or more vectors or plasmids whichtogether contain the total DNA to be introduced into the genome of thehost cell, or a transposon.

Host Cells

The host cell of the invention, either comprising a DNA construct or anexpression vector comprising the DNA sequence encoding the polypeptideof the first aspect, e.g., a hybrid enzyme, is advantageously used as ahost cell in the recombinant production of the hybrid enzyme, wild typeenzyme or a genetically modified wild type enzyme. The cell may betransformed with an expression vector. Alternatively, the cell may betransformed with the DNA construct of the invention encoding the hybridenzyme or a genetically modified wild type enzyme, conveniently byintegrating the DNA construct (in one or more copies) in the hostchromosome. Integration of the DNA construct into the host chromosomemay be performed according to conventional methods, e.g., by homologousor heterologous recombination.

The host cell may be any appropriate prokaryotic or eukaryotic cell,e.g., a bacterial cell, a filamentous fungus cell, a yeast cell, a plantcell or a mammalian cell.

Isolating and Cloning a DNA Sequence Encoding a Parent Endo-Amylase

The techniques used to isolate or clone a DNA sequence encoding thepolypeptide of the first aspect, e.g., a hybrid enzyme, are known in theart and include isolation from genomic DNA, preparation from cDNA, or acombination thereof. The cloning of the DNA sequences of the presentinvention from such genomic DNA can be effected, e.g., by using the wellknown polymerase chain reaction (PCR) or antibody screening ofexpression libraries to detect cloned DNA fragments with sharedstructural features. See, e.g., Innis et al., 1990, PCR: A Guide toMethods and Application, Academic Press, New York. Other DNAamplification procedures such as ligase chain reaction (LCR), ligatedactivated transcription (LAT) and DNA sequence-based amplification(NASBA) may be used.

The DNA sequence encoding a parent endo-amylase may be isolated from anycell or microorganism producing the endo-amylase in question, usingvarious methods well known in the art. First, a genomic DNA and/or cDNAlibrary should be constructed using chromosomal DNA or messenger RNAfrom the organism that produces the endo-amylase to be studied. Then, ifthe amino acid sequence of the endo-amylase is known, labeledoligonucleotide probes may be synthesized and used to identifyendo-amylase-encoding clones from a genomic library prepared from theorganism in question. Alternatively, a labelled oligonucleotide probecontaining sequences homologous to another known endo-amylase gene couldbe used as a probe to identify endo-amylase-encoding clones, usinghybridization and washing conditions of very low to very highstringency.

Yet another method for identifying endo-amylase-encoding clones wouldinvolve inserting fragments of genomic DNA into an expression vector,such as a plasmid, transforming endo-amylase-negative bacteria with theresulting genomic DNA library, and then plating the transformed bacteriaonto agar containing a substrate for endo-amylase (i.e. maltose),thereby allowing clones expressing the endo-amylase to be identified.

Alternatively, the DNA sequence encoding the enzyme may be preparedsynthetically by established standard methods, e.g., thephosphoroamidite method described S. L. Beaucage and M. H. Caruthers,(1981), Tetrahedron Letters 22, p. 1859-1869, or the method described byMatthes et al. (1984), EMBO J. 3, p. 801-805. In the phosphoroamiditemethod, oligonucleotides are synthesized, e.g., in an automatic DNAsynthesizer, purified, annealed, ligated and cloned in appropriatevectors.

Finally, the DNA sequence may be of mixed genomic and synthetic origin,mixed synthetic and cDNA origin or mixed genomic and cDNA origin,prepared by ligating fragments of synthetic, genomic or cDNA origin (asappropriate, the fragments corresponding to various parts of the entireDNA sequence), in accordance with standard techniques. The DNA sequencemay also be prepared by polymerase chain reaction (PCR) using specificprimers, for instance as described in U.S. Pat. No. 4,683,202 or R. K.Saiki et al. (1988), Science 239, 1988, pp. 487-491.

Isolated DNA Sequence

The present invention relates, inter alia, to an isolated DNA sequencecomprising a DNA sequence encoding a polypeptide of the first aspect,e.g., a hybrid enzyme.

The term “isolated DNA sequence” as used herein refers to a DNAsequence, which is essentially free of other DNA sequences, e.g., atleast about 20% pure, preferably at least about 40% pure, morepreferably at least about 60% pure, even more preferably at least about80% pure, and most preferably at least about 90% pure as determined byagarose electrophoresis.

For example, an isolated DNA sequence can be obtained by standardcloning procedures used in genetic engineering to relocate the DNAsequence from its natural location to a different site where it will bereproduced. The cloning procedures may involve excision and isolation ofa desired DNA fragment comprising the DNA sequence encoding thepolypeptide of interest, insertion of the fragment into a vectormolecule, and incorporation of the recombinant vector into a host cellwhere multiple copies or clones of the DNA sequence will be replicated.An isolated DNA sequence may be manipulated in a variety of ways toprovide for expression of the polypeptide of interest. Manipulation ofthe DNA sequence prior to its insertion into a vector may be desirableor necessary depending on the expression vector. The techniques formodifying DNA sequences utilizing recombinant DNA methods are well knownin the art.

DNA Construct

The present invention relates, inter alia, to a DNA construct comprisinga DNA sequence encoding a polypeptide of the first aspect. “DNAconstruct” is defined herein as a DNA molecule, either single- ordouble-stranded, which is isolated from a naturally occurring gene orwhich has been modified to contain segments of DNA, which are combinedand juxtaposed in a manner, which would not otherwise exist in nature.The term DNA construct is synonymous with the term expression cassettewhen the DNA construct contains all the control sequences required forexpression of a coding sequence of the present invention.

Site-Directed Mutagenesis

Once a parent endo-amylase-encoding DNA sequence suitable for use in apolypeptide of the first aspect has been isolated, and desirable sitesfor mutation identified, mutations may be introduced using syntheticoligonucleotides. These oligonucleotides contain nucleotide sequencesflanking the desired mutation sites. In a specific method, asingle-stranded gap of DNA, the endo-amylase-encoding sequence, iscreated in a vector carrying the endo-amylase gene. Then the syntheticnucleotide, bearing the desired mutation, is annealed to a homologousportion of the single-stranded DNA. The remaining gap is then filled inwith DNA polymerase I (Klenow fragment) and the construct is ligatedusing T4 ligase. A specific example of this method is described inMorinaga et al. (1984), Biotechnology 2, p. 646-639. U.S. Pat. No.4,760,025 disclose the introduction of oligonucleotides encodingmultiple mutations by performing minor alterations of the cassette.However, an even greater variety of mutations can be introduced at anyone time by the Morinaga method, because a multitude ofoligonucleotides, of various lengths, can be introduced.

Another method for introducing mutations into endo-amylase-encoding DNAsequences is described in Nelson and Long, (1989), AnalyticalBiochemistry 180, p. 147-151. It involves the 3-step generation of a PCRfragment containing the desired mutation introduced by using achemically synthesized DNA strand as one of the primers in the PCRreactions. From the PCR-generated fragment, a DNA fragment carrying themutation may be isolated by cleavage with restriction endonucleases andreinserted into an expression plasmid.

Localized Random Mutagenesis

The random mutagenesis may be advantageously localized to a part of theparent endo-amylase in question. This may, e.g., be advantageous whencertain regions of the enzyme have been identified to be of particularimportance for a given property of the enzyme, and when modified areexpected to result in a variant having improved properties. Such regionsmay normally be identified when the tertiary structure of the parentenzyme has been elucidated and related to the function of the enzyme.

The localized or region-specific, random mutagenesis is convenientlyperformed by use of PCR generated mutagenesis techniques as describedabove or any other suitable technique known in the art. Alternatively,the DNA sequence encoding the part of the DNA sequence to be modifiedmay be isolated, e.g., by insertion into a suitable vector, and saidpart may be subsequently subjected to mutagenesis by use of any of themutagenesis methods discussed above.

Expression of the Enzymes in Plants

A DNA sequence encoding an enzyme of interest, such as a hybrid enzymeof the present invention, may be transformed and expressed in transgenicplants as described below.

The transgenic plant can be dicotyledonous or monocotyledonous, forshort a dicot or a monocot. Examples of monocot plants are grasses, suchas meadow grass (blue grass, Poa), forage grass such as Festuca, Lolium,temperate grass, such as Agrostis, and cereals, e.g., wheat, oats, rye,barley, rice, sorghum and maize (corn).

Examples of dicot plants are tobacco, legumes, such as lupins, potato,sugar beet, pea, bean and soybean, and cruciferous plants (familyBrassicaceae), such as cauliflower, oil seed rape and the closelyrelated model organism Arabidopsis thaliana.

Examples of plant parts are stem, callus, leaves, root, fruits, seeds,and tubers as well as the individual tissues comprising these parts,e.g., epidermis, mesophyll, parenchyme, vascular tissues, meristems. Inthe present context, also specific plant cell compartments, such aschloroplast, apoplast, mitochondria, vacuole, peroxisomes and cytoplasmare considered to be a plant part. Furthermore, any plant cell, whateverthe tissue origin, is considered to be a plant part. Likewise, plantparts such as specific tissues and cells isolated to facilitate theutilisation of the invention are also considered plant parts e.g.,embryos, endosperms, aleurone and seeds coats.

Also included within the scope of the invention are the progeny of suchplants, plant parts and plant cells.

The transgenic plant or plant cell expressing the enzyme of interest maybe constructed in accordance with methods known in the art. In short theplant or plant cell is constructed by incorporating one or moreexpression constructs encoding the enzyme of interest into the planthost genome and propagating the resulting modified plant or plant cellinto a transgenic plant or plant cell.

Conveniently, the expression construct is a DNA construct whichcomprises a gene encoding the enzyme of interest in operable associationwith appropriate regulatory sequences required for expression of thegene in the plant or plant part of choice. Furthermore, the expressionconstruct may comprise a selectable marker useful for identifying hostcells into which the expression construct has been integrated and DNAsequences necessary for introduction of the construct into the plant inquestion (the latter depends on the DNA introduction method to be used).

The choice of regulatory sequences, such as promoter and terminatorsequences and optionally signal or transit sequences is determined,e.g., on the basis of when, where and how the enzyme is desired to beexpressed. For instance, the expression of the gene encoding the enzymeof the invention may be constitutive or inducible, or may bedevelopmental, stage or tissue specific, and the gene product may betargeted to a specific cell compartment, tissue or plant part such asseeds or leaves. Regulatory sequences are, e.g., described by Tague etal, Plant, Phys., 86, 506, 1988.

For constitutive expression the 35S-CaMV, the maize ubiquitin 1 and therice actin 1 promoter may be used (Franck et al. 1980. Cell 21: 285-294,Christensen AH, Sharrock R A and Quail 1992. Maize polyubiquitin genes:structure, thermal perturbation of expression and transcript splicing,and promoter activity following transfer to protoplasts byelectroporation. Plant Mo. Biol. 18, 675-689.; Zhang W, McElroy D. andWu R 1991, Analysis of rice Act1 5′ region activity in transgenic riceplants. Plant Cell 3, 1155-1165). Organ-specific promoters may, e.g., bea promoter from storage sink tissues such as seeds, potato tubers, andfruits (Edwards & Coruzzi, 1990. Annu. Rev. Genet. 24: 275-303), or frommetabolic sink tissues such as meristems (Ito et al., 1994. Plant Mol.Biol. 24: 863-878), a seed specific promoter such as the glutelin,prolamin, globulin or albumin promoter from rice (Wu et al., Plant andCell Physiology Vol. 39, No. 8 pp. 885-889 (1998)), a Vicia fabapromoter from the legumin B4 and the unknown seed protein gene fromVicia faba described by Conrad U. et al, Journal of Plant PhysiologyVol. 152, No. 6 pp. 708-711 (1998), a promoter from a seed oil bodyprotein (Chen et al., Plant and cell physiology vol. 39, No. 9 pp.935-941 (1998), the storage protein napA promoter from Brassica napus,or any other seed specific promoter known in the art, e.g., as describedin WO 91/14772. Furthermore, the promoter may be a leaf specificpromoter such as the rbcs promoter from rice or tomato (Kyozuka et al.,Plant Physiology Vol. 102, No. 3 pp. 991-1000 (1993), the chlorellavirus adenine methyltransferase gene promoter (Mitra, A. and Higgins, DW, Plant Molecular Biology Vol. 26, No. 1 pp. 85-93 (1994), or the aldPgene promoter from rice (Kagaya et al., Molecular and General GeneticsVol. 248, No. 6 pp. 668-674 (1995), or a wound inducible promoter suchas the potato pin2 promoter (Xu et al, Plant Molecular Biology Vol. 22,No. 4 pp. 573-588 (1993). Likewise, the promoter may inducible byabiotic treatments such as temperature, drought or alterations insalinity or induced by exogenously applied substances that activate thepromoter e.g., ethanol, oestrogens, plant hormones like ethylene,abscisic acid and gibberellic acid and heavy metals.

A promoter enhancer element may be used to achieve higher expression ofthe enzyme in the plant. For instance, the promoter enhancer element maybe an intron which is placed between the promoter and the nucleotidesequence encoding the enzyme. For instance, Xu et al. op cit disclosethe use of the first intron of the rice actin 1 gene to enhanceexpression.

The selectable marker gene and any other parts of the expressionconstruct may be chosen from those available in the art.

The DNA construct is incorporated into the plant genome according toconventional techniques known in the art, includingAgrobacterium-mediated transformation, virus-mediated transformation,micro injection, particle bombardment, biolistic transformation, andelectroporation (Gasser et al, Science, 244, 1293; Potrykus, Bio/Techn.8, 535, 1990; Shimamoto et al, Nature, 338, 274, 1989).

Presently, Agrobacterium tumefaciens mediated gene transfer is themethod of choice for generating transgenic dicots (for review Hooykas &Schilperoort, 1992. Plant Mol. Biol. 19: 15-38), and can also be usedfor transforming monocots, although other transformation methods oftenare used for these plants. Presently, the method of choice forgenerating transgenic monocots supplementing the Agrobacterium approachis particle bombardment (microscopic gold or tungsten particles coatedwith the transforming DNA) of embryonic calli or developing embryos(Christou, 1992. Plant J. 2: 275-281; Shimamoto, 1994. Curr. Opin.Biotechnol. 5: 158-162; Vasil et al., 1992. Bio/Technology 10: 667-674).An alternative method for transformation of monocots is based onprotoplast transformation as described by Omirulleh S, et al., PlantMolecular biology Vol. 21, No. 3 pp. 415-428 (1993).

Following transformation, the transformants having incorporated theexpression construct are selected and regenerated into whole plantsaccording to methods well-known in the art. Often the transformationprocedure is designed for the selective elimination of selection geneseither during regeneration or in the following generations by usinge.g., co-transformation with two separate T-DNA constructs or sitespecific excision of the selection gene by a specific recombinase.

Dough-Based Products

The hybrid enzyme of the present invention may be used for thepreparation of a dough-based edible product such as, bread, tortillas,cakes, pancakes, biscuits, cookies, pie crusts, more preferably bakedproducts, such as, bread products.

The dough used to prepare the dough based product generally comprisesflour, e.g., from grains, such as, wheat flour, corn flour, rye flour,oat flour, or sorghum flour. The dough is generally leavened by theaddition of a suitable yeast culture, such as a culture of Saccharomycescerevisiae (baker's yeast) or a chemical leavening agent.

The edible dough based product may preferably be any kind of bakedproduct prepared from dough, either of a soft or a crisp character,either of a white, light or dark type. Preferred edible dough basedproducts include bread (in particular white, wheat, whole-meal,low-carb, brown, multi-grain, dark and rye bread), typically in the formof loaves, buns or rolls, and more preferably, pan bread, hamburgerbuns, French baguette-type bread, pita bread, tortillas, cakes,pancakes, biscuits, cookies, pie crusts, crisp bread, steamed bread,pizza crust and the like.

The edible dough-based product is made by heating the dough, e.g., bybaking or steaming. Examples are steamed or baked bread (in particularwhite, whole-meal or rye bread), typically in the form of loaves orrolls. The edible dough based product may also be prepared by frying(e.g., deep frying in hot fat or oil). An example of such an edibleproduct is a doughnut.

The hybrid enzyme of the first aspect of the invention preferably have ahigh tolerance towards overdosing. The addition of the polypeptide ofthe invention, e.g., the polypeptide of the first aspect, in 2 times, 3times, preferably 4 times, more preferably 5 times, most preferably 6times the effective dosage of said polypeptide to a dough results in anELR and/or an ELR_(N) of less than 15%, less than 10%, less than 7%,less than 6%, less than 5%, less than 4% or even less than 3%.

In a further aspect the polypeptide of the invention has a residualactivity of at least 20%, such as at least 25% or 30%, preferably atleast 35%, more preferably at least 40% and most preferably at least50%, at the test conditions given in the specification.

The polypeptide of the present invention may further have an improvedexo-to-endo ratio de-fined as IEF1 or IEF2 in the specification. TheIEF1 or IEF2 of the polypeptide may be larger than 1, such as 1.1 or1.5, preferably 2 or 2.5 or 3, more preferably 3.5 or 4, most preferably5 or 7 or 10.

In further embodiments the invention provides polypeptides withcharacteristics that are of particular interest for baking purposes,namely a residual activity of at least 25% at 70° C. at the testconditions given in the specification, an increased exo-to-endo ratio(IEF), where IEF is larger than 1, and finally a reduced cohesiveness ofless than 5% (at the test conditions given in the specification) whilechange in hardness is at least 85 units (at the test conditions given inthe specification) and/or change mobility of free water is at least 1100units (at the test conditions given in the specification).

For baking purpose the polypeptide of the invention may give acohesiveness reduction, when measured at the test conditions given inthe specification, of at least 5%, while dHard-ness, when measured atthe test conditions given in the specification, is at least 85 units,such as 90 units or 100 units, preferably 150 units or 200 units, morepreferably 250 units or 300 units, most preferably 400 units or 600units. In a further embodiment the polypeptide of the invention may givea cohesiveness reduction, when measured at the test conditions given inthe specification, of at least 4%, while dHardness, when measured at thetest condi-tions given in the specification, is at least 85 units, suchas 90 units or 100 units, preferably 150 units or 200 units, morepreferably 250 units or 300 units, most preferably 400 units or 600units. In a still further embodiment the polypeptide of the inventionmay give a cohesive-ness reduction, when measured at the test conditionsgiven in the specification, of at least 2%, while dHardness, whenmeasured at the test conditions given in the specification, is at least85 units, such as 90 units or 100 units, preferably 150 units or 200units, more prefera-bly 250 units or 300 units, most preferably 400units or 600 units. In yet another embodiment the polypeptide of theinvention may give a cohesiveness reduction, when measured at the testconditions given in the specification, of at least 1%, while dHardness,when measured at the test conditions given in the specification, is atleast 85 units, such as 90 units or 100 units, preferably 150 units or200 units, more preferably 250 units or 300 units, most prefera-bly 400units or 600 units.

When the polypeptide of the invention is added together with 300 MANUNovamyl®/kg flour it may give a cohesiveness reduction, when measured atthe test conditions given in the specification, of at least 5%, whiledHardness, when measured at the test conditions given in thespecification, is at least 15 units, such as 20 units or 30 units,preferably 40 units or 50 units, more preferably 60 units or 70 units,most preferably 85 units or 100 units. In a further embodiment thepolypeptide of the invention may give a cohesiveness reduction, whenmeasured at the test conditions given in the specification, of at least4%, while dHardness, when measured at the test conditions given in thespecification, is at least 15 units, such as 20 units or 30 units,preferably 40 units or 50 units, more preferably 60 units or 70 units,most preferably 85 units or 100 units. In a still further embodiment thepolypeptide of the invention may give a cohesiveness reduction, whenmeasured at the test conditions given in the specification, of at least2%, while dHardness, when measured at the test conditions given in thespecification, is at least 15 units, such as 20 units or 30 units,preferably 40 units or 50 units, more preferably 60 units or 70 units,most preferably 85 units or 100 units. In yet another embodiment thepolypeptide of the invention may give a cohesiveness reduction, whenmeasured at the test conditions given in the specification, of at least1%, while dHardness, when measured at the test conditions given in thespecification, is at least 15 units, such as 20 units or 30 units,preferably 40 units or 50 units, more preferably 60 units or 70 units,most preferably 85 units or 100 units.

For baking purpose the polypeptide of the invention may give acohesiveness reduction, when measured at the test conditions given inthe specification, of at least 5%, while dMobil-ity, when measured atthe test conditions given in the specification, is at least 300 units,such as 400 units or 500 units, preferably 600 units or 700 units, morepreferably 800 units or 900 units, most preferably 1000 units or 1200units. In a further embodiment the polypeptide of the invention may givea cohesiveness reduction, when measured at the test conditions given inthe specification, of at least 4%, while dMobility, when measured at thetest condi-tions given in the specification, is at least 300 units, suchas 400 units or 500 units, prefera-bly 600 units or 700 units, morepreferably 800 units or 900 units, most preferably 1000 units or 1200units. In a still further embodiment the polypeptide of the inventionmay give a cohe-siveness reduction, when measured at the test conditionsgiven in the specification, of at least 2%, while dMobility, whenmeasured at the test conditions given in the specification, is at least300 units, such as 400 units or 500 units, preferably 600 units or 700units, more preferably 800 units or 900 units, most preferably 1000units or 1200 units. In yet another embodiment the polypeptide of theinvention may give a cohesiveness reduction, when measured at the testconditions given in the specification, of at least 1%, while dMobility,when measured at the test conditions given in the specification, is atleast 300 units, such as 400 units or 500 units, preferably 600 units or700 units, more preferably 800 units or 900 units, most preferably 1000units or 1200 units.

When the polypeptide of the invention is added together with 300 MANUNovamyl®/kg flour it may give a cohesiveness reduction, when measured atthe test conditions given in the specification, of at least 5%, whiledMobility, when measured at the test conditions given in thespecification, is at least 1000 units, such as 1100 units or 1200 units,preferably 1400 units or 1500 units, more preferably 1800 units or 2000units, most preferably 2200 units or 2500 units. In a further embodimentthe polypeptide of the invention may give a cohesive-ness reduction,when measured at the test conditions given in the specification, of atleast 4%, while dMobility, when measured at the test conditions given inthe specification, is at least 1000 units, such as 1100 units or 1200units, preferably 1400 units or 1500 units, more preferably 1800 unitsor 2000 units, most preferably 2200 units or 2500 units. In a stillfurther embodiment the polypeptide of the invention may give acohesiveness reduction, when measured at the test conditions given inthe specification, of at least 2%, while dMobility, when measured at thetest conditions given in the specification, is at least 1000 units, suchas 1100 units or 1200 units, preferably 1400 units or 1500 units, morepreferably 1800 units or 2000 units, most preferably 2200 units or 2500units. In yet another embodiment the poly-peptide of the invention maygive a cohesiveness reduction, when measured at the test con-ditionsgiven in the specification, of at least 1%, while dMobility, whenmeasured at the test conditions given in the specification, is at least1000 units, such as 1100 units or 1200 units, preferably 1400 units or1500 units, more preferably 1800 units or 2000 units, most preferably2200 units or 2500 units.

The above values for cohesiveness reduction, dHardness and dMobility areparticularly rele-vant for bread, in particular for bread prepared bythe sponge and dough method. Similar correlation between cohesivenessreduction and dHardness and dMobility is disclosed in Example 7.

The hybrid enzyme of the present invention may optionally be usedtogether with one or more additional enzymes and/or anti-staling agents.

Anti-staling agents include but are not limited to emulsifiers,hydrocolloids and enzymatic anti-staling agents. As used herein, ananti-staling agent refers to a chemical, biological or enzymatic agentwhich can retard staling of the dough-based products, that is, which canreduce the rate deterioration of the softness of the dough based productduring storage. The softness of dough based products (and theanti-staling effect of the anti-staling agent) can be evaluatedempirically by the skilled test baker or measured using a textureanalyzer (e.g., TAXT2), as is known in the art.

Examples of chemical anti-staling agents include polar lipids, e.g.,fatty acids and their monoglyceride esters, such as, described in U.S.Pat. No. 4,160,848.

In a preferred embodiment, the anti-staling agent is an anti-stalingenzyme, which is preferably added to the dough prior to cooking (e.g.,baking). Examples of anti-staling enzymes include, without limitation,endo-amylases, such as the hybrids of the invention, exo-endo-amylases,such as, e.g., the exo-amylase described in U.S. Pat. No. 6,667,065 andUS 2004/0043109, pullulanases, glycosyltransferases, amyloglycosidases,branching enzymes (1,4-alpha-glyucan branching enzyme),4-alpha-glucanotransferases (dextrin transferase), beta-amylases,maltogenic alpha-amylases, lipases, phospholipases, galactolipases,acyltransferases, pectate lyases, xylanases, xyloglucanendotransglycosylases, proteases, e.g., as described in WO 2003/084331,peptidases and combinations thereof.

The amylase may be from a fungus, bacterium or plant. It may be anendo-amylase, e.g., from Bacillus, particularly B. licheniformis or B.amyloliquefaciens, a beta-amylase, e.g., from plant (e.g., soy bean) orfrom microbial sources (e.g., Bacillus), such as the non-maltogenicBacillus clausii alpha-amylase disclosed in WO9950399A2, the Pseudomonassaccharophilia amylase in SEQ ID NO:1 of WO 2004111217, or aglucoamylase, or a fungal endo-amylase, e.g., from A. niger or A.oryzae.

More preferably, the additional enzyme is an anti-staling enzyme andpreferably the anti-staling enzyme is a maltogenic amylase (EC3.2.1.133). The maltogenic amylases is added into the dough in an amounteffective to retard the staling of the product, such as, at least 500MANU/kg flour, more preferably in an amount of at least 500 to 1500MANU/kg flour. A maltogenic amylase may be obtained from any suitablesource, such as derived from a bacteria, such as Bacillus, preferably B.stearothermophilus, e.g., from strain NCIB 11837 or a variant thereofmade by amino acid modification (EP 494233 B1, U.S. Pat. No. 6,162,628).The maltogenic amylase may preferably be added at a dosage of 20 to 2000MANU/kg flour, preferably 500 to 1000 MANU/kg flour, more preferably, atleast 750 MANU/kg flour, at least 1000 MANU/kg flour. A preferredmaltogenic amylase is Novamyl® (available form Novozymes A/S).

In another preferred embodiment, the anti-staling enzyme is a xylanase.The xylanase may be obtained from any suitable source, e.g., fromBacillus, e.g., Bacillus subtilis, as described in WO 2003/010923, WO2001/066711 or WO 2000/039289, and Aspergillus, in particular of A.aculeatus, A. niger, A. awamori, or A. tubigensis or Trichoderma andThermomyces as described in WO 96/32472, e.g., T reesei, or from astrain of Humicola, e.g., H. insolens. Optionally, an additional enzymemay be used together with the above anti-staling enzymes, such as, alipolytic enzyme, particularly phospholipase, galactoilipase and/ortriacyl glycerol lipase activity, e.g., as described in WO 9953769, WO0032758, WO 0200852 or WO 2002066622. or e.g., a transglutaminase, acellulytic enzyme, e.g., a cellulase, an acyltransferase, a proteindisulfide isomerase, a pectinase, a pectate lyase, an oxidoreductase.The enzyme may be of any origin, including mammalian, plant, andpreferably microbial (bacterial, yeast or fungal) origin and may beobtained by techniques conventionally used in the art.

The additional enzyme may also be a lipolytic enzyme, particularlyphospholipase, galactoilipase and/or triacyl glycerol lipase activity,e.g., as described in WO 9953769, WO 0032758, WO 0200852 or WO2002066622.

Further, the additional enzyme may be a second amylase, a cyclodextringlucanotransferase, a protease or peptidase, in particular anexopeptidase, a trans-glutaminase, a lipase, a phospholipase, acellulase, a hemicellulase, a glycosyltransferase, a branching enzyme(1,4-alpha-glucan branching enzyme) or an oxidoreductase. The additionalenzyme may be of mammalian, plant or microbial (bacterial, yeast orfungal) origin.

The second amylase may be from a fungus, bacterium or plant. It may be amaltogenic amylase (EC 3.2.1.133), e.g., from B. stearothermophilus, anendo-amylase, e.g., from Bacillus, particularly B. licheniformis or B.amyloliquefaciens, a beta-amylase, e.g., from plant (e.g., soy bean) orfrom microbial sources (e.g., Bacillus), a glucoamylase, e.g., from A.niger, or a fungal endo-amylase, e.g., from A. oryzae or fromPseudomonas saccharophilia such as the non-maltogenic alpha-amylasedisclosed in WO9950399A2.

The hemicellulase may be a pentosanase, e.g., a xylanase which may be ofmicrobial origin, e.g., derived from a bacterium or fungus, such as astrain of Aspergillus, in particular of A. aculeatus, A. niger, A.awamori, or A. tubigensis, from a strain of Trichoderma, e.g., T.reesei, or from a strain of Humicola, e.g., H. insolens.

The protease may be from Bacillus, e.g., B. amyloliquefaciens.

The oxidoreductase may be a glucose oxidase, a carbohydrate oxidase, ahexose oxidase, a lipoxidase, a peroxidase, or a laccase.

Dough and/or Bread-Improving Additive

The hybrid enzyme of the present invention may be provided as a doughand/or bread improving additive in the form of a granulate oragglomerated powder. The dough and/or bread improving additive maypreferably have a narrow particle size distribution with more than 95%(by weight) of the particles in the range from 25 to 500 μm.

In a preferred embodiment a composition, e.g., a bread improvingadditive, is produced in a process comprising the steps of; a) providinga first amino acid sequence having endo-amylase activity; b) providing asecond amino acid sequence comprising a carbohydrate-binding module; c)and constructing a polypeptide comprising said first amino acid sequenceand second amino acid sequence; d) providing a DNA sequence encodingsaid polypeptide; e) expressing said DNA sequence in a suitable hostcell and recovering said polypeptide; f) adding said polypeptide toflour or to a granulate or agglomerated powder.

Granulates and agglomerated powders may be prepared by conventionalmethods, e.g., by spraying the amylase, i.e. the hybrid enzyme, onto acarrier in a fluid-bed granulator. The carrier may consist ofparticulate cores having a suitable particle size. The carrier may besoluble or insoluble, e.g., a salt (such as NaCl or sodium sulfate), asugar (such as sucrose or lactose), a sugar alcohol (such as sorbitol),starch, rice, corn grits, or soy.

Starch Processing

The polypeptide of this invention, i.e. an endo-amylase having a CBM,possesses valuable properties allowing for a variety of industrialapplications. In particular, enzymes of the first aspect are applicableas a component in washing, dishwashing and hard-surface cleaningdetergent compositions. Numerous variants are particularly useful in theproduction of sweeteners and ethanol from starch, and/or for textiledesizing. One example of producing ethanol, wherein an endo-amylase ofthe invention may be used is disclosed in U.S. Pat. No. 5,231,017 whichis hereby incorporated by reference.

Further, a process wherein an endo-amylase of the invention may be usedis disclosed in DK patent application PA 2003 01568 (hereby incorporatedby reference). Said process comprises hydrolysing starch into a solublestarch hydrolysate at a temperature below the initial gelatinizationtemperature of said granular starch. Another suitable process isdisclosed in WO2004081193 (hereby incorporated by reference).

Conditions for conventional starch-conversion processes, includingstarch liquefaction and/or saccharification processes are described in,e.g., U.S. Pat. No. 3,912,590 and in EP patent publications Nos. 252,730and 63,909.

A preferred use is in a fermentation process wherein a starch substrateis liquefied and/or saccharified in the presence of the endo-amylasehaving a CBM to produce glucose and/or maltose, e.g., for use assweeteners or suitable for conversion into a fermentation product by afermenting organism, preferably a yeast. Such fermentation processesinclude a process for producing ethanol for fuel or drinking ethanol(portable alcohol), a process for producing a beverage, a process forproducing organic compounds, such as citric acid, itaconic acid, lacticacid, gluconic acid; ketones; amino acids, such as glutamic acid (sodiummonoglutaminate), but also more complex compounds such as antibiotics,such as penicillin, tetracyclin; enzymes; vitamins, such as riboflavin,B12, beta-carotene; hormones, which are difficult to producesynthetically.

Production of Sweeteners from Starch:

A “traditional” process for conversion of starch to fructose syrupsnormally consists of three consecutive enzymatic processes, viz. aliquefaction process followed by a saccharification process and anisomerization process. During the liquefaction process, starch isdegraded to dextrins by an endo-amylase, preferably by an endo-amylasehaving a CBM, such as the polypeptide of the invention at pH valuesbetween 5.5 and 6.2 and at temperatures of 95-160° C. for a period ofapprox. 2 hours. In order to ensure an optimal enzyme stability underthese conditions, 1 mM of calcium is added (40 ppm free calcium ions).

After the liquefaction process the dextrins are converted into dextroseby addition of a g-lucoamylase (e.g., AMG™) and a debranching enzyme,such as an isoamylase or a pullulanase (e.g., Promozyme™). Before thisstep the pH is reduced to a value below 4.5, maintaining the hightemperature (above 95° C.), and the liquefying endo-amylase activity isdenatured. The temperature is lowered to 60° C., and glucoamylase anddebranching enzyme are added. The sac-charification process proceeds for24-72 hours.

After the saccharification process the pH is increased to a value in therange of 6-8, preferably pH 7.5, and the calcium is removed by ionexchange. The dextrose syrup is then converted into high fructose syrupusing, e.g., an immmobilized glucoseisomerase (such as Sweetzyme™).

In an embodiment of a starch process of the invention, milledgelatinized whole grain raw material is broken down (hydrolyzed) intomaltodextrins (dextrins) mostly of a DE higher than 4 using thepolypeptide of the first aspect. The raw material is in one embodimentof the invention milled (whole) grain.

In an embodiment of the invention, enzymatic liquefaction is carried outas a three-step hot slurry process. The slurry is heated to between60-95° C., preferably 80-85° C., and the enzyme(s) is(are) added toinitiate liquefaction (thinning), at least a polypeptide of the firstaspect is added. Then the slurry is jet-cooked at a temperature between95-140° C., preferably 105-125° C. to complete gelanitization of theslurry. Then the slurry is cooled to 60-95° C. and more enzyme(s),preferably comprising the polypeptide of the first aspect, is (are),added to finalize hydrolysis (secondary liquefaction). The liquefactionprocess is carried out at pH 4.5-6.5, in particular at a pH between 5and 6. Milled and liquefied whole grains are known as mash. Thepolypeptide of the first aspect may be added in effective amounts wellknown to the person skilled in the art.

In an aspect the process may comprise; a) contacting a starch substratewith a endo-amylase having a CBM, e.g., the polypeptide of the firstaspect; b) incubating said starch substrate with said polypeptide and afungal alpha-amylase and/or or a glucoamylase for a time and at atemperature sufficient to achieve liquefaction and saccharification ofat least 90%, or at least 92%, at least 94%, at least 95%, at least 96%,at least 97%, at least 98%, at least 99%, at least 99.5% w/w of saidstarch substrate into fermentable sugars; c) fermenting to produce afermentation product, d) optionally recovering the fermentation product.

In yet another aspect the process comprising liquefaction and/orhydrolysis of a slurry of gelatinized or granular starch, in particularliquefaction and/or hydrolysis of granular starch into a soluble starchhydrolysate at a temperature below the initial gelatinizationtemperature of said granular starch. In addition to being contacted witha polypeptide of the invention, e.g, the polypeptide of the firstaspect, the starch may be contacted with an enzyme selected from thegroup consisting of; a fungal alpha-amylase (EC 3.2.1.1), a beta-amylase(E.C. 3.2.1.2), and a glucoamylase (E.C.3.2.1.3). In an embodimentfurther a debranching enzyme, such as an isoamylase (E.C. 3.2.1.68) or apullulanases (E.C. 3.2.1.41) may be added.

In an embodiment the process is conducted at a temperature below theinitial gelatinization temperature. Preferably the temperature at whichthe processes are conducted is at least 30° C., at least 31° C., atleast 32° C., at least 33° C., at least 34° C., at least 35° C., atleast 36° C., at least 37° C., at least 38° C., at least 39° C., atleast 40° C., at least 41° C., at least 42° C., at least 43° C., atleast 44° C., at least 45° C., at least 46° C., at least 47° C., atleast 48° C., at least 49° C., at least 50° C., at least 51° C., atleast 52° C., at least 53° C., at least 54° C., at least 55° C., atleast 56° C., at least 57° C., at least 58° C., at least 59° C., orpreferably at least 60° C. The pH at which the process is conducted mayin be in the range of 3.0 to 7.0, preferably from 3.5 to 6.0, or morepreferably from 4.0-5.0. In a preferred embodiment the process comprisesfermentation, e.g with a yeast to produce ethanol, e.g., at atemperature around 32° C., such as from 30 to 35° C. During thefermentation the ethanol content reaches at least 7%, at least 8%, atleast 9%, at least 10% such as at least 11%, at least 12%, at least 13%,at least 14%, at least 15% such as at least 16% ethanol (w/w).

The starch slurry to be used in any of the above aspects may have 20-55%dry solids granular starch, preferably 25-40% dry solids granularstarch, more preferably 30-35% dry solids granular starch. After beingcontacted with the endo-amylase having a CBM, e.g, the polypeptide ofthe first aspect at least 85%, at least 86%, at least 87%, at least 88%,at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, orpreferably at least 99% of the dry solids of the granular starch isconverted into a soluble starch hydrolysate.

In another preferred embodiment the endo-amylase having a CBM, e.g, thepolypeptide of the first aspect, is used in a process for liquefaction,saccharification of a gelatinized starch, e.g., but not limited togelatinization by jet cooking. The process may comprise fermentation toproduce a fermentation product, e.g., ethanol. Such a process forproducing ethanol from starch-containing material by fermentationcomprises: (i) liquefying said starch-containing material with aendo-amylase having a CBM, e.g, the polypeptide of the first aspect;(ii) saccharifying the liquefied mash obtained; (iii) fermenting thematerial obtained in step (ii) in the presence of a fermenting organism.Optionally the process further comprises recovery of the ethanol. Thesaccharification and fermentation may be carried out as a simultaneoussaccharification and fermentation process (SSF process). During thefermentation the ethanol content reaches at least 7%, at least 8%, atleast 9%, at least 10% such as at least 11%, at least 12%, at least 13%,at least 14%, at least 15% such as at least 16% ethanol.

The starch to be processed in the processes of the above aspects may inparticular be obtained from tubers, roots, stems, legumes, cereals orwhole grain. More specifically the granular starch may be obtained fromcorns, cobs, wheat, barley, rye, milo, sago, cassaya, tapioca, sorghum,rice, peas, bean, banana or potatoes. Specially contemplated are bothwaxy and non-waxy types of corn and barley.

Compositions of the Invention

The invention also relates to a composition comprising the polypeptideof the first aspect. The composition may further comprise an enzymeselected from the group comprising of; a fungal alpha-amylase (EC3.2.1.1), a beta-amylase (E.C. 3.2.1.2), a glucoamylase (E.C.3.2.1.3)and a pullulanases (E.C. 3.2.1.41). The glucoamylase may preferably bederived from a strain of Aspergillus sp., such as Aspergillus niger, orfrom a strain of Talaromyces sp. and in particular derived fromTalaromyces leycettanus such as the glucoamylase disclosed in U.S. Pat.No. Re. 32,153, Talaromyces duponti and/or Talaromyces thermopiles suchas the glucoamylases disclosed in U.S. Pat. No. 4,587,215 and morepreferably derived from Talaromyces emersonii. Most preferably theglucoamylase is derived from Talaromyces emersonii strain CBS 793.97and/or having the sequence disclosed as SEQ ID NO: 7 in WO 99/28448.Further preferred is a glucoamylase which has an amino acid sequencehaving at least 50%, at least 60%, at least 70%, at least 80%, at least90% or even at least 95% homology to the aforementioned amino acidsequence. A commercial Talaromyces glucoamylase preparation is suppliedby Novozymes A/S as Spirizyme Fuel.

Also preferred for a composition comprising the polypeptide of the firstaspect and a glucoamylase are polypeptides having glucoamylase activitywhich are derived from a strain of the genus Trametes, preferablyTrametes cingulata. Further preferred is polypeptides havingglucoamylase activity and havering at least 50%, at least 60%, at least70%, at least 80%, at least 90% or even at least 95% homology with aminoacids for mature polypeptide amino acids 1 to 575 of SEQ ID NO: 5 inU.S. Patent application 60/650,612.

Also preferred for a composition comprising the polypeptide of the firstaspect and a glucoamylase are polypeptides having glucoamylase activitywhich are derived from a strain of the genus Pachykytospora, preferablyPachykytospora papyracea. Further preferred is polypeptides havingglucoamylase activity and havering at least 50%, at least 60%, at least70%, at least 80%, at least 90% or even at least 95% homology with aminoacids for mature polypeptide amino acids 1 to 556 of SEQ ID NO: 2 inU.S. Patent application 60/650,612.

The composition described above may be used for liquefying and/orsaccharifying a gelatinized or a granular starch, as well as a partlygelatinized starch, e.g. in a production of sweetener, or a fermentationprocess, such as for ethanol. A partly gelatinized starch is a starchwhich to some extent is gelatinized, i.e. wherein part of the starch hasirreversibly swelled and gelatininized and part of the starch is stillpresent in a granular state.

The composition described above may also comprise an acid fungalalpha-amylase present in an amount of 0.01 to 10 AFAU/g DS, preferably0.1 to 5 AFAU/g DS, more preferably 0.5 to 3 AFAU/AGU, and mostpreferably 0.3 to 2 AFAU/g DS. The composition may be applied in any ofthe starch processes described above.

Production of Fermentation Products

From gelatinized starch: In this aspect the present invention relates toa process for producing a fermentation product, especially ethanol, fromstarch-containing material, which process includes a liquefaction stepand separately or simultaneously performed saccharification andfermentation step(s). The fermentation product, such as especiallyethanol, may optionally be recovered after fermentation, e.g., bydistillation. Suitable starch-containing starting materials are listedin the section “Starch-containing materials”-section below. Contemplatedenzymes are listed in the “Enzymes”-section below. The fermentation ispreferably carried out in the presence of yeast, preferably a strain ofSaccharomyces. Suitable fermenting organisms are listed in the“Fermenting Organisms”-section below.

A preferred process comprises a) contacting an aqueous starch slurrywith a polypeptide comprising a first amino acid sequence havingalpha-amylase activity and a second amino acid sequence comprising acarbohydrate-binding module, b) incubating said starch slurry with saidpolypeptide, c) fermenting to produce a fermentation product, and d)optionally recovering the fermentation product. Preferably the step b)is performed for a time and at a temperature sufficient to achieveconversion of at least 90% w/w of said starch substrate into fermentablesugars. Preferably the first amino acid sequence and/or second aminoacid sequence of said polypeptide is derived from a bacterium. Saidpolypeptide may preferably be the hybrid of the first aspect.

The aqueous slurry may contain from 10-40 wt-%, preferably 25-35 wt-%starch-containing material. The slurry is heated to above thegelatinization temperature and bacterial and/or acid fungalalpha-amylase may be added to initiate liquefaction (thinning). Theslurry may in an embodiment be jet-cooked to further gelatinize theslurry before being subjected to an alpha-amylase in step (a) of theinvention.

More specifically liquefaction may be carried out as a three-step hotslurry process. The slurry is heated to between 60-95° C., preferably80-85° C., and alpha-amylase is added to initiate liquefaction(thinning). Then the slurry may be jet-cooked at a temperature between95-140° C., preferably 105-125° C., for 1-15 minutes, preferably for3-10 minute, especially around 5 minutes. The slurry is cooled to 60-95°C. and more alpha-amylase is added to finalize hydrolysis (secondaryliquefaction). The liquefaction process is usually carried out at pH4.5-6.5, in particular at a pH between 5 and 6. Milled and liquefiedwhole grains are known as mash.

The saccharification in step may be carried out using conditions wellknow in the art. For instance, a full saccharification process may lastsup to from about 24 to about 72 hours, however, it is common only to doa pre-saccharification of typically 40-90 minutes at a temperaturebetween 30-65° C., typically about 60° C., followed by completesaccharification during fermentation in a simultaneous saccharificationand fermentation process (SSF). Saccharification is typically carriedout at temperatures from 30-65° C., typically around 60° C., and at a pHbetween 4 and 5, normally at about pH 4.5.

The most widely used process in ethanol production is the simultaneoussaccharification and fermentation (SSF) process, in which there is noholding stage for the saccharification, meaning that fermentingorganism, such as yeast, and enzyme(s) may be added together. When doingSSF it is common to introduce a pre-saccharification step at atemperature above 50° C., just prior to the fermentation.

In accordance with the present invention the fermentation step (c)includes, without limitation, fermentation processes used to producealcohols (e.g., ethanol, methanol, butanol); organic acids (e.g., citricacid, acetic acid, itaconic acid, lactic acid, gluconic acid); ketones(e.g., acetone); amino acids (e.g., glutamic acid); gases (e.g., H₂ andCO₂); antibiotics (e.g., penicillin and tetracycline); enzymes; vitamins(e.g., riboflavin, B12, beta-carotene); and hormones. Preferredfermentation processes include alcohol fermentation processes, as arewell known in the art. Preferred fermentation processes are anaerobicfermentation processes, as are well known in the art.

From un-gelatinized starch: In this embodiment the invention relates toprocesses for producing a fermentation product from starch-containingmaterial without gelatinization of the starch-containing material. Inone embodiment a polypeptide of the invention, e.g. the hybrid enzyme ofthe first aspect, and optionally a glucoamylase is used duringsaccharification and fermentation. According to the invention thedesired fermentation product, such as ethanol, can be produced withoutliquefying the aqueous slurry containing the starch-containing material.In one embodiment a process of the invention includes saccharifyingmilled starch-containing material below the initial gelatinizationtemperature in the presence of the hybrid enzyme of the first aspect anda glucoamylase to produce sugars that can be fermented into the desiredfermentation product by a suitable fermenting organism.

A preferred process comprises a) contacting an aqueous granular starchslurry with a polypeptide comprising a first amino acid sequence havingalpha-amylase activity and a second amino acid sequence comprising acarbohydrate-binding module, b) incubating said starch slurry with saidpolypeptide, c) fermenting to produce a fermentation product, and d)optionally recovering the fermentation product. Preferably the step b)is performed for a time and at a temperature sufficient to achieveconversion of at least 90% w/w of said starch substrate into fermentablesugars. Preferably the first amino acid sequence and/or second aminoacid sequence of said polypeptide is derived from a bacterium. Saidpolypeptide may preferably be the hybrid of the first aspect.

The term “initial gelatinization temperature” means the lowesttemperature at which gelatinization of the starch commences. Starchheated in water begins to gelatinize between 50° C. and 75° C.; theexact temperature of gelatinization depends on the specific starch, andcan readily be determined by the skilled artisan. Thus, the initialgelatinization temperature may vary according to the plant species, tothe particular variety of the plant species as well as with the growthconditions. In the context of this invention the initial gelatinizationtemperature of a given starch-containing material is the temperature atwhich birefringence is lost in 5% of the starch granules using themethod described by Gorinstein. S. and Lii. C., Starch/Stärke, Vol. 44(12) pp. 461-466 (1992).

Before step (a) a slurry of starch-containing material, such as granularstarch, having 20-55 wt.-% dry solids, preferably 2540 wt.-% dry solids,more preferably 30-35% dry solids of starch-containing material may beprepared. The slurry may include water and/or process waters, such asstillage (backset), scrubber water, evaporator condensate or distillate,side stripper water from distillation, or other fermentation productplant process water. Because the process of the invention is carried outbelow the gelatinization temperature and thus no significant viscosityincrease takes place, high levels of stillage may be used if desired. Inan embodiment the aqueous slurry contains from about 1 to about 70vol.-% stillage, preferably 15-60% vol.-% stillage, especially fromabout 30 to 50 vol.-% stillage.

The milled starch-containing material may be prepared by millingstarch-containing material to a particle size of 0.05 to 3.0 mm,preferably 0.1-0.5 mm. After being subjected to a process of theinvention at least 85%, at least 86%, at least 87%, at least 88%, atleast 89%, at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, orpreferably at least 99% of the dry solids of the starch-containingmaterial is converted into a soluble starch hydrolysate.

The process of the invention is conducted at a temperature below theinitial gelatinization temperature. Preferably the temperature at whichstep (a) is carried out is between 30-75° C., preferably between 45-60°C.

In a preferred embodiment step (a) and step (b) are carried out as asimultaneous saccharification and fermentation process. In suchpreferred embodiment the process is typically carried at a temperaturebetween 28° C. and 36° C., such as between 29° C. and 35° C., such asbetween 30° C. and 34° C., such as around 32° C. According to theinvention the temperature may be adjusted up or down duringfermentation.

In an embodiment simultaneous saccharification and fermentation iscarried out so that the sugar level, such as glucose level, is kept at alow level such as below about 3 wt.-%, preferably below about 2 wt.-%,more preferred below about 1 wt.-%., even more preferred below about0.5%, or even more preferred below about 0.1 wt. %. Such low levels ofsugar can be accomplished by simply employing adjusted quantities ofenzyme and fermenting organism. A skilled person in the art can easilydetermine which quantities of enzyme and fermenting organism to use. Theemployed quantities of enzyme and fermenting organism may also beselected to maintain low concentrations of maltose in the fermentationbroth. For instance, the maltose level may be kept below about 0.5 wt.-%or below about 0.2 wt.-%.

The process of the invention may be carried out at a pH in the rangebetween 3 and 7, preferably from 3.5 to 6, or more preferably from 4 to5.

Starch-Containing Materials

Any suitable starch-containing starting material, including granularstarch, may be used according to the present invention. The startingmaterial is generally selected based on the desired fermentationproduct. Examples of starch-containing starting materials, suitable foruse in a process of present invention, include tubers, roots, stems,whole grains, corns, cobs, wheat, barley, rye, milo, sago, cassaya,tapioca, sorghum, rice peas, beans, or cereals, sugar-containing rawmaterials, such as molasses, fruit materials, sugar, cane or sugar beet,potatoes, and cellulose-containing materials, such as wood or plantresidues. Contemplated are both waxy and non-waxy types of corn andbarley.

The term “granular starch” means raw uncooked starch, i.e., starch inits natural form found in cereal, tubers or grains. Starch is formedwithin plant cells as tiny granules insoluble in water. When put in coldwater, the starch granules may absorb a small amount of the liquid andswell. At temperatures up to 50° C. to 75° C. the swelling may bereversible. However, with higher temperatures an irreversible swellingcalled “gelatinization” begins. Granular starch to be processed may be ahighly refined starch quality, preferably at least 90%, at least 95%, atleast 97% or at least 99.5% pure or it may be a more crude starchcontaining material comprising milled whole grain including non-starchfractions such as germ residues and fibers. The raw material, such aswhole grain, is milled in order to open up the structure and allowingfor further processing. Two milling processes are preferred according tothe invention: wet and dry milling. In dry milling whole kernels aremilled and used. Wet milling gives a good separation of germ and meal(starch granules and protein) and is often applied at locations wherethe starch hydrolysate is used in production of syrups. Both dry and wetmilling is well known in the art of starch processing and is equallycontemplated for the process of the invention.

The starch-containing material is milled in order to expose more surfacearea. In an embodiment the particle size is between 0.05 to 3.0 mm,preferably 0.1-0.5 mm, or so that at least 30%, preferably at least 50%,more preferably at least 70%, even more preferably at least 90% of themilled starch-containing material fit through a sieve with a 0.05 to 3.0mm screen, preferably 0.1-0.5 mm screen.

Fermentation Product

The term “fermentation product” means a product produced by a processincluding a fermentation step using a fermenting organism. Fermentationproducts contemplated according to the invention include alcohols (e.g.,ethanol, methanol, butanol); organic acids (e.g., citric acid, aceticacid, itaconic acid, lactic acid, gluconic acid); ketones (e.g.,acetone); amino acids (e.g., glutamic acid); gases (e.g., H₂ and CO₂);antibiotics (e.g., penicillin and tetracycline); enzymes; vitamins(e.g., riboflavin, B₁₂, beta-carotene); and hormones. In a preferredembodiment the fermentation product is ethanol, e.g., fuel ethanol;drinking ethanol, i.e., potable neutral spirits; or industrial ethanolor products used in the consumable alcohol industry (e.g., beer andwine), dairy industry (e.g., fermented dairy products), leather industryand tobacco industry. Preferred beer types comprise ales, stouts,porters, lagers, bitters, malt liquors, happoushu, high-alcohol beer,low-alcohol beer, low-calorie beer or light beer. Preferred fermentationprocesses used include alcohol fermentation processes, as are well knownin the art. Preferred fermentation processes are anaerobic fermentationprocesses, as are well known in the art.

Fermenting Organisms

“Fermenting organism” refers to any organism, including bacterial andfungal organisms, suitable for use in a fermentation process and capableof producing desired a fermentation product. Especially suitablefermenting organisms are able to ferment, i.e., convert, sugars, such asglucose or maltose, directly or indirectly into the desired fermentationproduct. Examples of fermenting organisms include fungal organisms, suchas yeast. Preferred yeast includes strains of Saccharomyces spp., inparticular, Saccharomyces cerevisiae.

In a preferred embodiment the fermenting organism, e.g. the yeast, maybe transformed with the polypeptide of the first aspect and applied in aprocess comprising; a) contacting a starch substrate with a fermentingorganism cell transformed to express a polypeptide comprising a firstamino acid sequence having alpha-amylase activity and a second aminoacid sequence comprising a carbohydrate-binding module; b) holding saidstarch substrate with said yeast for a time and at a temperaturesufficient to achieve conversion of at least 90% w/w of said starchsubstrate into fermentable sugars; c) fermenting to produce afermentation product, e.g., ethanol, d) optionally recovering thefermentation product, e.g., ethanol. The steps a, b, and c are performedseparately or simultaneously. In a preferred embodiment the first aminoacid sequence and/or second amino acid sequence of said polypeptide isderived from a bacterium.

Materials and Methods

KNU amylolytic activity: The amylolytic activity may be determined usingpotato starch as substrate. This method is based on the break-down ofmodified potato starch by the enzyme, and the reaction is followed bymixing samples of the starch/enzyme solution with an iodine solution.Initially, a blackish-blue colour is formed, but during the break-downof the starch the blue colour gets weaker and gradually turns into areddish-brown, which is compared to a coloured glass standard.

One Kilo Novo alfa Amylase Unit (KNU) is defined as the amount of enzymewhich, under standard conditions (i.e. at 37° C.+/−0.05; 0.0003 M Ca²⁺;and pH 5.6) dextrinizes 5.26 g starch dry substance Merck Amylumsolubile. A folder AF 9/6 describing this analytical method in moredetail is available upon request to Novozymes A/S, Denmark, which folderis hereby included by reference.

Endo activity assay: Endo endo-amylase activity may be determined usingthe Endo activity assay. 1 mL resuspended Phadebas substrate (0.25tablets/mL 50 mM sodium acetate, 1 mM CaCl₂, adjusted to pH 5.7) isincubated with 25 microL enzyme for 15 min at 40° C. with agitation. Thereaction is stopped by addition of 0.5 mL 1 M NaOH and the mixture iscentrifuged in a table centrifuge at 14,000 RPM. The absorbance of thesupernatant at 620 nm is measured. The activity is determined bycomparing to a standard with declared activity (BAN 480 L, 480 KNU/g).

Maltogenic amylase activity: One MANU (Maltogenic Amylase Novo Unit) maybe defined as the amount of enzyme required to release one micromol ofmaltose per minute at a concentration of 10 mg of maltotriose (Sigma M8378) substrate per ml of 0.1 M citrate buffer, pH 5.0 at 37° C. for 30minutes (MANU unit further defined in U.S. Pat. No. 6,162,628, which ishereby incorporated by reference).

DNA Manipulations

Unless otherwise stated, DNA manipulations and transformations wereperformed using standard methods of molecular biology as described inSambrook et al. (1989) Molecular cloning: A laboratory manual, ColdSpring Harbor lab. Cold Spring Harbor, N.Y.; Ausubel, F. M. et al.(eds.) “Current protocols in Molecular Biology”, John Wiley and Sons,1995; Harwood, C. R. and Cutting, S. M. (eds.).

EXAMPLE 1 Construction of Hybrids Between an Endo-Amylase and the CBMfrom AMY1048

The amylase AMY1048 is a wild type Bacillus amylase made up of acatalytic fragment of 484 amino acid and in addition a CBM20 fragment of101 aa. The DNA sequence coding the AMY1048 is included as SEQ ID NO:1and the mature AMY1048 sequence is included as SEQ ID NO:2. In SEQ IDNO:1 the CBM is defined as amino acid residues 485 to 586 whichcorrespond to nucleotides 1540-1845 in SEQ ID NO:2. The amylaseincluding the CBM can be expressed from a construction similar to whathave been described for other amylases i.e. e.g., inserted into a vectorunder the control of a constitutive active promoter and flanked by thesignal sequence (SEQ ID NO: 15) and the terminator sequence of B.licheniformis endo-amylase.

Replacing the catalytic fragment of the AMY1048 endo-amylase with acatalytic domain of another endo-amylase, thus creating a hybrid of theCBM from AMY1048 and a new endo-amylase, is made by amplifying the DNAfragment coding the catalytic domain of the new amylase by PCR using twooligonucleotides. The sense oligonucleotide is in it's 5′end identicalto the last 20 nucleotide of the DNA sequence coding for the signalsequence prior the AMY1048 mature sequence and further in it's 3′end isidentical to the first 20 nucleotides of DNA sequence coding the maturepart of the desire amylase DNA. The antisense oligonucleotides are init's 5′end identical to the antisense DNA of the first 20 nucleotide ofthe DNA sequence coding the CBM from AMY1048 and further in it's 3′endis identical to the antisense of the last 20 nucleotides of the DNAsequence coding the mature part of the desire amylase DNA.

Both the amplified amylase DNA and the vector hosting the AMY1048amylase, is digested with Sac II and Sca I and the vector and PCRfragments ligated prior to transferring into Bacillus subtilis strainSHA273. In the primer sequences below the recognition sites of therestriction enzymes are indicated by underscore.

To construct a hybrid of the B. licheniformis endo-amylase (SEQ IDNO:35) and the CBM20 from B. flavothermus amylase the followingoligonucleotides were used by the present inventors: Sense:5′-ctcattctgcagccgcggcagcaaatcttaatgggacgct-3′. (P1s SEQ ID NO:19)Antisence: 5′-atttgggaagtagtacttattctttgaacataaattgaaa-3′. (P1as SEQ IDNO:20)

The resulting DNA sequence coding the mature polypeptide and the aminoacid sequence of the mature polypeptide are included as SEQ ID NO:3 andSEQ ID NO:4 respectively

To construct a hybrid of the LE429 variant of B. licheniformisendo-amylase (SEQ ID NO:41) and the CBM20 from B. flavothermus amylasethe following oligonucleotides were used: Sense:5′-ctcattctgcagccgcggcagtaaatggcacgctgatgca-3′. (P2s SEQ ID NO:21)Antisence: 5′-atttgggaagtagtacttatttttggaacataaattgaaa-3′. (P2as SEQ IDNO:22)

The resulting DNA sequence coding the mature polypeptide and the aminoacid sequence of the mature polypeptide are included as SEQ ID NO:5 andSEQ ID NO:6 respectively To construct a hybrid of the B.Stearothermophilus endo-amylase (SEQ ID NO:36) and the CBM20 from B.flavothermus amylase the following oligonucleotides were used: Sense:5′-ctcattctgcagccgcggcagcaccgtttaacggctttaa-3′. (P3s SEQ ID NO:23)Antisence: 5′-atttgggaagtagtacttattttaggaacccaaaccgaaa-3′. (P3as SEQ IDNO:24)

The result DNA sequence coding the mature polypeptide and the amino acidsequence of the mature polypeptide are included as SEQ ID NO:7 and SEQID NO:8 respectively To construct a hybrid of a variant of the alkalineBacillus sp. SP722 endo-amylase (SEQ ID NO:38) and the CBM20 from B.flavothermus amylase the following oligonucleotides were used: Sense:5′ctcattctgcagccgcggcacatcataatgggacaaatgg-3′. (P4s SEQ ID NO:25)Antisence: 5′-atttgggaagtagtacttatccatttgtcccattatgatg-3′. (P4as SEQ IDNO:26)

The resulting DNA sequence coding the mature polypeptide and the aminoacid sequence of the mature polypeptide are included as SEQ ID NO:9 andSEQ ID NO:10 respectively.

To construct a hybrid of a variant of the alkaline Bacillus speciesAA560 endo-amylase (SEQ ID NO:40) and the CBM20 from B. flavothermusamylase the following oligonucleotides were used: Sense:5′-ctcattctgcagccgcggcacaccataatggtacgaacgg-3′ (P5s SEQ ID NO:27)Antisence: 5′-atttgggaagtagtacttattttgtttacccaaatagaaa-3′ (P5as SEQ IDNO:28)The resulting DNA sequence coding the mature polypeptide and the aminoacid sequence of the mature polypeptide are included as SEQ ID NO:11 andSEQ ID NO:12 respectively.

To construct a hybrid of a variant of the Bacillus amyloliquefacienceendo-amylase (SEQ ID NO:37) and the CBM20 from B. flavothermus amylasethe following oligonucleotides were used: Sense:5′-ctcattctgcagccgcggcagtaaatggcacgctgatgca-3′ (P6s SEQ ID NO:29)Antisence: 5′-atttgggaagtagtacttatttttggaacataaatggaga-3′ (P6as SEQ IDNO:30)

The resulting DNA sequence coding the mature polypeptide and the aminoacid sequence of the mature polypeptide are included as SEQ ID NO:13 andSEQ ID NO:14 respectively.

The above described hybrid enzymes was expressed by B. subtilis growingin shake flasks for 72 hours at and secreted into the supernatant. Thepresence of hybrid enzyme in the supernatant was demonstrated bySDS-PAGE.

EXAMPLE 2 Construction of a Hybrid Amylase with Carbohydrate BindingDomain

The catalytic fragment of the B. flavothermus endo-amylase, AMY1048 canfurther be divided into the central AB-domain harboring the catalyticcenter and a C domain c-terminal to the catalytic domain but prior tothe CBM. In SEQ ID NO:2 the catalytic core domain consist of the first397 amino acid residues, the C domain is defined as the amino acidresidues from 398 to 484 and the CBM is defined as amino acid residues485 to 586. In SEQ ID NO:1 the signal sequence is encoded by nucleotide1 to 87, the catalytic core domain is encoded by nucleotide 88-1278, theC domain is encoded by the nucleotides 1279-1539, and the CBM is encodedby nucleotide 1540-1845.

The amylase including the CBM can be expressed from a vectorconstruction similar to what have been described in WO0060060A2 inexample 4—i.e. the amylase gene is inserted into a vector under thecontrol of a amylase promoter and flanked by the signal sequence and theterminator sequence of B. licheniformis endo-amylase.

As an alternative to harboring the gene on a plasmid, the cassetteincluding the DNA sequence coding for the antibiotic marker, promoter,signal sequence, the mature protein and the terminator can be integratedinto the genome of the B. subtilis by homologous in-vivo crossover, byflanked upstream and downstream genomic DNA with high similarity to anon-essential part of the B. subtilis DNA. Useful DNA regions could bethe pectate lyase or the endo-amylase loci. In this example the AMY1048and the hybrid is inserted into the amylase loci in opposite directionrelative to the original B. subtilis amylase.

The catalytic core domain of the AMY1048 endo-amylase was replaced witha catalytic core domain of the Bacillus starothermophilus (BSG)endo-amylase, thus creating a hybrid of the C-domain and the CBM fromAMY1048 and the catalytic core domain from the new endo-amylase.

The DNA fragment coding the catalytic core of the B. stearothermophilusamylase (SEQ ID NO:36) was amplified by PCR using two oligonucleotides.The sense oligonucleotides were in it's 5′end identical to the last 20nucleotide of the DNA sequence (SEQ ID NO:15) coding for the signalsequence prior the AMY1048 mature sequence (SEQ ID NO:1) and further init's 3′end identical to the first 20 nucleotides of DNA sequence codingthe mature part of the desire amylase DNA. The antisenseoligonucleotides were in its 5′end identical to the antisense DNA of thefirst 20 nucleotide of the DNA sequence coding the C-domain from AMY1048and further in its 3′end was identical to the antisense of the last 20nucleotides of the DNA sequence coding the catalytic core of the BSGamylase DNA.

To construct a hybrid of the B. stearothermophilus endo-amylase coredomain and C-domain and the CBM20 from B. flavothermus amylase thefollowing oligonucleotides were used by the present inventors: Sense:5′-ctcattctgcagccgcggcagcaccgtttaacggctttaa-3′. (P7s SEQ ID NO:31)Antisence: 5′-atatagtcgtgctgtgttccgtaagcataatccctgcgcg-3′. (P7as SEQ IDNO:32)

To facilitate genome integration, a 5 kB fragment upstream from of thesignal sequence and into the amylase genome sequence is made by PCRusing the AMY1048 genomic construction as template, and the inverseprimer of the antisense primer and the genome specific primer:5′-ctgcatcagggctgcggcatcc-3; (P8 SEQ ID NO:33).

Another fragment from the termination of the gene and upstream of thegenomic B. subtilis amylase is made by PCR using the AMY1048 genomicconstruction as template, and the inverse primer of the sense primer andthe genome specific primer: 5′-ctgcatcagggctgcggcatcc-3′; (P9 SEQ IDNO:34).

Taking advantages of the 40 bp overlap, the three PCR fragments wereassembled by PCR and the resulting product amplified in another PCRusing the genome specific primers, prior to transferring into Bacillussubtilis strain SHA273 (described in WO92/11357 and WO95/10603).

The resulting DNA sequence coding the mature polypeptide and the maturepolypeptide are included as SEQ ID NO:17 and SEQ ID NO:18 respectively.

The hybrid enzyme was expressed by B. subtilis growing in PS1 media inshake flasks for 72 hours at 37° C. and secreted into the supernatant.The presence of hybrid enzyme in the supernatant was demonstrated bySDS-PAGE.

EXAMPLE 3 Determination of Exo-Endo Improvement Factor (EIF)

EIF is the measure of an increment of the exo/endo ratio relative to aparent enzyme i.e. EIF=(exo/endo of variant)/(exo/endo of parentenzyme). An enzyme has an increase in exo/endo ratio compared to itsparent enzyme if EIF>1. EIF may be based on one of the followingmethods.

EIF1 Endo activity assay: The Phadebas Amylase Test (PharmaciaDiagnostics) is run according to the suppliers recommenda-tions and theendo units calculated from the supplied formula where the naturallogarithm to the activ-ity equals N, where N=A+square root[B+C*ln(Abs)]. Abs is the absorbance at 620 nm, A=−13.3235, B=243.3293,and C=26.73797

Exo activity assay: 50 microL of 50 mM sodium citrate, 5 mM CaCl₂, pH6.5 is mixed with 25 microL of enzyme in the same buffer and 25 microLBetamyl substrate (Betamyl Method, Megazyme) dissolved according tosuppliers recommendations. The assay mix is incubated for 30 min. at 40°C. and the reaction stopped by adding 150 microL 4% (w/w) Trizma base(Tris(hydroxymethyl)-aminomethane). The activity is expressed directlyas the absorbance at 420 nm measured using a microtiter plate reader.

EIF2 Endo activity assay: 1 mL resuspended Phadebas substrate (PharmaciaDiagnostics) (0.25 tablets/mL 50 mM so-dium acetate, 1 mM CaCl₂,adjusted to pH 5.7) is incubated with 25 microL enzyme for 15 min at 40°C. with agitation. The reaction is stopped by addition of 0.25 mL 1 MNaOH and the mix-ture is centrifuged in a table centrifuge at 14,000RPM. The absorbance of the supernatant at 620 nm is measured. Theactivity is determined by comparing to a standard with declared activity(BAN 480 L, 480 KNU/g)

Exo activity assay: 900 microL 3.3% solubilized waxy maize starch (3.3%starch is boiled in 50 mM sodium acetate, 1 mM CaCl₂, pH 5.7 for 5 minand cooled to 40° C.) is incubated with 100 microL enzyme at 40° C. withstirring. After appropriate reaction time the remaining starch isprecipitated by addition of 450 microL 4° C. 96% ethanol. Theprecipitate is immediately removed by centrifugation at 3000 G for 20min. The total carbohydrate in the supernatant is determined by mixing200 microL supernatant with 50 microL 2% tryptophan and 900 microL 64%sulphuric acid. The mixture is heated for 15 min at 95° C. and theabsorbance at 630 nm is measured after cooling to room tem-perature. Theactivity is determined by comparing with the absorbance of glucosestandards in the same assay. One unit is defined as the amount of enzymethat at initial rates liberates 1 mg oligomeric products (products thatare not precipitated by ethanol) per min.

EXAMPLE 4 Liquefaction and Saccharification with an Endo-Amylase with aCBM

This example illustrates the conversion of granular wheat starch intoglucose using a bacterial endo-amylase with a CBM (SEQ ID NO:4) or thesame bacterial endo-amylase without CBM (SEQ ID NO:35) together with aglucoamylase and an acid fungal amylase. A slurry with 33% dry solids(DS) granular starch was prepared by adding 247.5 g of wheat starchunder stirring to 502.5 ml of water. The pH was adjusted with HCl to4.5. The granular starch slurry was distributed to 100 ml Erlenmeyerflasks with 75 g in each flask. The flasks were incubated with magneticstirring in a 60° C. water bath. At zero hours the enzyme activitiesgiven in table 1 were dosed to the flasks. Samples were withdrawn after24, 48 and 73 and 94 hours. The enzyme levels used were endo-amylase+/−CBM 100 KNU/kg DS, glucoamylase 200 AGU/kg DS, acid fungalalpha-amylase 50 AFAU/g DS

Total dry solids starch was determined using the following method. Thestarch was completely hydrolyzed by adding an excess amount ofendo-amylase (300 KNU/Kg dry solids) and placing the sample in an oilbath at 95° C. for 45 minutes. Subsequently the samples were cooled to60° C. and an excess amount of glucoamylase (600 AGU/kg DS) was addedfollowed by incubation for 2 hours at 60° C.

Soluble dry solids in the starch hydrolysate were determined byrefractive index measurement on samples after filtering through a 0.22microM filter. The sugar profile was determined by HPLC. The amount ofglucose was calculated as DX. The results are shown in table 2 and 3.TABLE 2 Soluble dry solids as percentage of total dry substance at 100KNU/kg DS endo-amylase dosage. Enzyme 24 hours 48 hours 73 hours 94hours Endo-amylase 83.7 87 89.7 90.3 Endo-amylase + CBM 87.2 89.7 91.592.3

TABLE 3 The DX of the soluble hydrolysate at 100 KNU/kg DS endo-amylasedosage. Enzyme 24 hours 48 hours 73 hours 94 hours Endo-amylase 72.082.0 83.8 83.8 Endo-amylase + CBM 76.7 87.0 87.5 87.5

EXAMPLE 5 Effective Dosage

The “effective dosage” of the amylase in question is defined as thedosage resulting in a reduction in firmness of more than 10%, e.g., ofbetween 10 and 20%, compared to the firmness of a bread without enzymes(the control). The reduction in firmness is measured after storage for14 days in inert atmosphere at room temperature.

Tolerance towards overdosing is measured by using the Elasticity LossRatio=ELR. ELR is measured day 1 after baking or later, such as day 5,day 10 or as in the example below after 14 days storage and is definedthen as follows:ELR%=(Elasticity_(control day 14)−Elasticity_(amylase day 14)×100)/Elasticity_(control day 14)

In combination with 450 MANU/kg flour Novamyl® the tolerance towardsoverdosing is measured:ELR _(N)%=(Elasticity_(Novamyl day 14)−Elasticity_(Novamyl day 14)×100)/Elasticity_(Novamyl day 14)

If the amylase is overdosed the ELR and/or ELR_(N) will be >5%.

Baking Process

Bread are baked according to the sponge & dough method.

Sponge, Ingredients as % on Flour Basis Soya oil 2.5 SSL 0.38 Yeast 5Wheat flour 60 Water 62

Dough, Ingredients as % on flour basis Ascorbic acid to be optimized foreach flour ADA 20 ppm Salt 2 Sirup 7 (dry substance) Water to beoptimized for each flour Wheat flour 40 Calcium propionate + enzymes0.25

The sponge ingredients yeast, water, flour, SSL and oil are mixed at 90rpm for 1 minutes, 150 rpm for 4 minutes. The sponge is set forfermentation for 3 hours at 27° C. and 86% RH. The sponge is added thedough ingredients and mixed to a dough at 90 rpm for 1 minute and at 150rpm for 14 minutes. The dough is scaled into pieces of 340 g each andrested for 10 minutes.

The dough portions are sheeted and molded followed by fermentation at 55minutes at 42° C. and 86% RH. The doughs are baked at 225° C. for 15minutes. The baked bread are cooled and stored until analysis.

Bread is baked with the CBM-hybrid enzyme and with the correspondingenzyme without a CBM. The effective dose is determined with and withoutaddition of Novamyl® at 450 MANU/kg flour. Firmness and elasticity of abread are measured by the TA.XT2 texture analyzer according to AACCmethod 74-09.

The effective dosage of the CBM-hybrid enzyme is determined and a newset of bread is baked with 3 and 5 times the effective dosage with andwithout addition of Novamyl® at 450 MANU/kg flour.

The ELR is measured after 14 days of storage, and it is found that theELR as well as the ELR_(N) is less than 5% for the amylase with CBMdosed 5 times the effective dosage whereas it is more than 5% for thecorresponding enzymes without addition of the CBM dosed 3 times theeffective dose.

EXAMPLE 6 Determination of ELR for Selected Variants

Example 6 was performed as described in Example 5 except that a dosageof 500 MANU/kg flour was used.

Two variants of a hybrid comprising the alkaline Bacillus species M560endo-amylase (SEQ ID NO:40) and the CBM20 from the B. flavothermusamylase (residues 485 to 586 in SEQ ID NO:2) were used: The variant BE1comprising the following alterations in the amylase sequence: R118K,D183*, G184*, N195F, R320K, R458K, N33S, D36N, K37L, E391I, Q394R,K395D, T452Y and N484P, and the variant BE2 comprising of the followingalterations in the amylase sequence: R118K, D183*, G184*, N195F, R320K,R458K and N484P. TABLE 1 Application of hybrid-amylase (1 mg/kg flour)without Novamyl Firmness Firmness on reduction in % Elasticity Treatmentday 15 (g) of control day 15 g/g ELR % Control 794 39.9 BE1 382 51 47.0−17.0 BE2 313 61 46.6 −16.8

TABLE 2 Application of hybrid-amylase in combination with NovamylFirmness Firmness on reduction in % of Elasticity ELR Treatment Day 15(g) control day 15 g/g % Control 706 40.8 BE1 0.5 mg/kg flour 316 5546.9 −4.5 BE1 1 mg/kg flour 239 66 47.0 −4.9 BE2 0.5 mg/kg flour 315 5547.0 −4.9 BE2 1 mg/kg flour 225 68 47.5 −6.0 Only Novamyl ® 452 44.8 500MANU/kg flour

EXAMPLE 7 Batter Cake

Batter cake dough was prepared with hybrids BE1, BE2, the Bacillusamylase shown in SEQ ID NO:40 (CD donor homologue) and the Bacillusamylases SEQ ID NO:2 (CBM donor).

The dough was made from a commercial batter cake mix “Tegral Allegro”from Puratos consisting of wheat flour, sugar, baking powder, emulsifier(mono- and diglycerides of fatty acids). The cake mix, enzyme (4 mg/kgflour) and water was place in a bowl and beat with a spatula, Bear AR 5A-Vari-mixer, at third speed until a smooth homogeneous mixture wasobtained (approximately 2 minutes). Molds were filled with 300 g doughand baked at 180 C for 45 minutes. The baked cakes were cooled at roomtemperature for 30 minutes and packed in nitrogen before storage at roomtemperature until analysis.

Mobility of free water was determined using low field NMR as describedby P. L. Chen, Z. Long, R. Ruan and T. P. Labuza, Nuclear MagneticResonance Studies of water Mobility in bread during Storage.Lebensmittel Wissenschaft und Technologie 30, 178-183 (1997).

Hardness and cohesiveness was measured according to the method describedin Food Texture and viscosity, 2^(nd) edition, Malcolm Bourne, FoodScience and Technology, International Series, Academic Press, page182-186.

All data were measured after 14 days. The following results wereobtained: Treatment Hardness units Cohesiveness units Mobility unitsReference 1485 34 4148 BE1 9.5 KNU/kg 1482 35 4655 flour Amyl1 1702 354811 9.5 KNU/kg flour BE3 9.5 KNU/kg 1217 34 4797 flour BAN (SEQ ID 145632 4423 NO: 37) 9.5 KNU/kg flourBased on the above data the following parameters (I)-(III) werecalculated:Cohesiveness reduction%=(Cohesiveness_(Reference)−Cohesiveness_(amyase))×100%/COhesiveness_(Reference)  (I)dHardness=Hardness_(Reference)−Hardness_(Amylase)  (II)dMobility=Mobility_(Amylase)−Mobility_(Reference)  (III) TreatmentCohesiveness Reference Reduction % dHardness units dMobility units BE19.5 KNU/kg −3 3 507 flour Amyl1 −3 −217 663 9.5 KNU/kg flour BE3 0 268649 9.5 KNU/kg flour BAN (SEQ ID 5.8 20 275 NO: 37) 9.5 KNU/kg flourAmyl1 is identical to the amylase of SEQ ID NO: 40 with the followingsubstitutions: R118K, D183*, G184*, N195F, R320K, R458K, N33S, D36N,K37L, E391I, Q394R, K395D, T452Y and N484P, using the numbering of SEQID NO: 40.

EXAMPLE 8 Sponge and Dough

Bread were baked according to the sponge & dough method. Bread werestored at room temperature for 14 days until analysis. Hardness andcohesiveness was measured according to the method described in FoodTexture and viscosity, 2 edition, Malcolm Bourne, Food Science andTechnology, International Series, Academic Press, page 182-186, andmobility of free water was determined using low field NMR as describedby P. L. Chen, Z. Long, R. Ruan and T. P. Labuza, Nuclear MagneticResonance Studies of water Mobility in bread during Storage.Lebensmittel Wissenschaft und Technologie 30, 178-183 (1997). Threeamylases were used; the variants BE1 and BE3 and the Bacillus amylaseSEQ ID NO:2 (CBM donor). The variant BE3 has a the catalytic domainhaving the amino acid sequence as shown in SEQ.ID: 37 and comprise oneor more, e.g. such as all of the following alterations: S31A, D32N,133L, E178*, G179*, N190F, K3891, K392R, E393D, V508A and a CBM havingthe amino acid sequence shown as amino acid residues 485 to 586 in SEQID NO:2.

All data were measured after 14 days. The following results wereobtained: Hardness Cohesiveness Mobility Treatment units units unitsReference 400 38 6435 Novamyl 272 48 6234 300 MANU/kg flour BE3 0.05mg/kg flour + 256 48 7365 Novamyl 300 MANU/kg flour BAN (SEQ ID 207 457354 NO: 37) 0.05 mg/kg flour + Novamyl 300 MANU/kg flour BE3 0.15 mg/kgflour 223 48 6886 BE1 0.5 mg/kg flour 311 41 7152Based on the above data the following parameters (I)-(VI) werecalculated:For treatments without Novamyl®Cohesiveness reduction%=(Cohesiveness_(Novamyl)−Cohesiveness_(amyase+Novamyl))×100%/COhesiveness_(Novamyl)  (IV)dHardness=Hardness_(Novamyl)−Hardness_(Amylase+Novamyl)  (V)dMobility=Mobility_(Amylase+Novamyl)−Mobility_(Novamyl)  (VI)For treatments with Novamyl®Cohesiveness reduction%=(Cohesiveness_(Reference)−Cohesiveness_(amyase))×100%/COhesiveness_(Reference)  (I)dHardness=Hardness_(Reference)−Hardness_(Amylase)  (II)dMobility=Mobility_(Amylase)−Mobility_(Reference)  (III) CohesivenessdHardness dMobility Treatment reduction % units units Reference Novamyl300 MANU/kg flour BE3 0.05 mg/kg flour + 0 16 1131 Novamyl 300 MANU/kgflour BAN (SEQ ID 6.3 65 1120 NO: 37) 0.05 mg/kg flour + Novamyl 300MANU/kg flour BE3 0.15 mg/kg flour −26 177 451 BE1 0.5 mg/kg flour −7.989 717

EXAMPLE 9 Determination of Thermostablity

The thermostability was determined at 60, 65 or 70° C. for 30 minutes ina 50 mM NaOAc, 1 mM CaCl₂ buffer at pH 5.7. The samples was cooled downand the residual activity was measured using the Phadebas method asdescribe in section Materials and Methods except that the determinationtook place at 50° C. The residual activity (R.A.) can be calculatedaccording to the following equation: R.A. (%)=[Abs (heat treated)−Abs(blank)]/[Abs (heat treated at 60 C)−Abs (blank)]*100%.

The following results were obtained:

Residual activity for Fungamyl, a well-known fungal baking amylase fromA. oryzae, and to hybrid enzymes of the invention. Enzyme 60° C. 65° C.70° C. Fungamyl 100 4 2 BE1 100 78 67 BE3 100 80 27

1. polypeptide which polypeptide is a hybrid comprising; a) a firstamino acid sequence having endo-amylase activity and b) a second aminoacid sequence comprising a carbohydrate-binding module.
 2. Thepolypeptide of claim 1, wherein said first amino acid sequence and/orsaid second amino is derived from a bacterium
 3. The polypeptideaccording to claim 1, wherein said second amino acid sequence has atleast 60% identity to the amino acid sequence shown as amino acidresidues 485 to 586 in SEQ ID NO:2.
 4. The polypeptide according toclaim 1, wherein said first amino acid sequence has at least 60%identity to any amino acid sequence selected from the group consistingof SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39,SEQ ID NO:40, SEQ ID NO:41 and SEQ ID NO:42.
 5. The polypeptideaccording to claim 1, having at least 60% identity to any amino acidsequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:6,SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14.
 6. Thepolypeptide according to claim 1, comprising a) the catalytic domainshown in SEQ ID NO:40 or a homologous catalytic domain, wherein one ormore, or preferably all, of the following substitutions have beenintroduced: R118K, D183*, G184*, N195F, R320K, R458K, N33S, D36N, K37L,E391I, Q394R, K395D, T452Y and N484P, using the numbering of SEQ ID NO:40 and b) the CBM shown as residue 485 to 585 of SEQ ID NO:2.
 7. Thepolypeptide according to claim 1 comprising a) the catalytic domainshown in SEQ.ID: 37 or a homologous catalytic domain and comprising oneor more, e.g. such as all of the following alterations: S31A, D32N,133L, E178*, G179*, N190F, K3891, K392R, E393D, V508A and b) the CBMhaving the amino acid sequence shown as amino acid residues 485 to 586in SEQ ID NO:2.
 8. The polypeptide according to claim 1 comprising a)the catalytic domain shown in SEQ ID NO:40 or a homologous catalyticdomain, wherein one or more, or preferably all, of the followingsubstitutions have been introduced: R118K, D183*, G184*, N195F, R320K,R458K and N484P, using the numbering of SEQ ID NO: and b) the CBM shownas residue 485 to 585 of SEQ ID NO:2.
 9. The polypeptide according toclaim 1, wherein said polypeptide has; a) an EIF1 larger than 1.0 at thetest conditions given in the specification, or b) an EIF2 larger than1.0 at the test conditions given in the specification.
 10. Thepolypeptide according to claim 1, wherein said polypeptide has at least25% residual activity at 70° C. at the test conditions given in thespecification.
 11. The polypeptide according to claim 1, wherein theaddition of 2 times the effective dosage of said polypeptide to a doughresults in an ELR of less than 15%.
 12. The polypeptide according toclaim 1, wherein the addition of 2 times the effective dosage of saidpolypeptide to a dough results in an ELR_(N) of less than 15%.
 13. Aprocess for preparing a dough or an edible product made from a dough,which process comprises adding the polypeptide according to claim 1 tothe dough.
 14. The process of claim 13 wherein the edible product is abaked product.
 15. The process of claim 13 wherein the addition of 2times the effective dosage of said polypeptide results in an ELR of lessthan 15%.
 16. The process according to claim 13 wherein the addition of2 times the effective dosage of said polypeptide results in an ELR_(N)of less than 15%.
 17. The process according to claim 13 wherein thepolypeptide gives a cohesiveness reduction of less than 5% when dosed togive a dHardness of at least 85 units at the test conditions given inthe specification.
 18. The process according to claim 13 wherein thepolypeptide when added together with 300 MANU Novamyl/kg flour gives acohesiveness reduction of less than 5% when dosed to give a dHardness ofat least 15 units at the test conditions given in the specification 19.The process according to claim 13 wherein the polypeptide gives acohesiveness reduction of less than 5% when dosed to give a dMobility ofat least 400 units at the test conditions given in the specification 20.The process according to claim 13 wherein the polypeptide when addedtogether with 300 MANU Novamyl/kg flour gives a cohesiveness reductionof less than 5% when dosed to give a dMobility of at least 1100 units atthe test conditions given in the specification 21-52. (canceled)